Peripheral Neuropathies
Neuropathies associated with cytomegalovirus infection
Nov. 16, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Herpes zoster oticus …
- Updated 05.14.2024
- Released 11.17.2003
- Expires For CME 05.14.2027
Herpes zoster oticus
Introduction
Overview
The author explains the clinical presentation, pathophysiology, diagnostic work-up, and management of herpes zoster oticus, ie, a form of herpes zoster with peripheral facial nerve impairment due to varicella-zoster virus. The Advisory Committee on Immunization Practices (ACIP) now recommends recombinant varicella-zoster virus vaccine (Shingrix) over live-attenuated varicella-zoster virus vaccine (Zostavax) for herpes zoster prevention, and, furthermore, recommends that healthy adults aged 50 years or older, including those who have already received live-attenuated varicella-zoster virus vaccine (Zostavax), be vaccinated with two doses of recombinant varicella-zoster virus vaccine (Shingrix) (2 to 6 months apart). Multiple cranial nerve involvement is rare in herpes zoster oticus, but when present, appears to worsen prognosis for recovery of facial paresis and hearing loss.
Key points
|
• Herpes zoster oticus can be considered as peripheral facial nerve impairment (motor and/or sensory) due to varicella-zoster virus, with or without associated rash, and is associated with otologic manifestations or other neurologic complications, including cranial polyneuropathy or meningitis. | |
|
• Herpes zoster oticus is a specific form of herpes zoster that often presents with pre-eruptive (“pre-herpetic”) pain, allodynia, burning, or itching generally localized to the ear and mastoid region. Facial palsy may precede, occur simultaneously with, or follow erythematous maculopapular rash in herpes zoster oticus. | |
|
• A small proportion of cases of facial palsy associated with varicella-zoster infection do not have an associated rash (or at least no rash in the expected location in the internal auditory canal or on the tympanic membrane), a condition referred to as “zoster sine herpete.” | |
|
• Impaired cell-mediated immunity is an important factor in reactivation of varicella-zoster virus and development of clinical herpes zoster. | |
|
• Secondary prevention of herpes zoster is now possible for older adults previously infected with chickenpox. The United States Food and Drug Administration (FDA) licensed a live-attenuated varicella-zoster virus vaccine (Zostavax) in 2006 for use in people aged 60 years and older, and in March 2011, the FDA approved the use of live-attenuated varicella-zoster virus vaccine (Zostavax) in adults aged 50 through 59 years. In October 2017, the FDA approved an adjuvanted, recombinant varicella-zoster virus vaccine (Shingrix - GSK) for use in people aged 50 years and older. | |
|
• The Advisory Committee on Immunization Practices now recommends recombinant varicella-zoster virus vaccine (Shingrix) over live-attenuated varicella-zoster virus vaccine (Zostavax) for herpes zoster prevention and, furthermore, recommends that healthy adults aged 50 years or older, including those who have already received live-attenuated varicella-zoster virus vaccine (Zostavax), be vaccinated with two doses of recombinant varicella-zoster virus vaccine (Shingrix) (2 to 6 months apart). | |
|
• Multiple cranial nerve involvement is rare in herpes zoster oticus, but when present, appears to worsen prognosis for recovery of facial paresis and hearing loss. |
Historical note and terminology
Clinical observations in the late 19th century suggested that both chickenpox and herpes zoster were caused by the same process (234). This concept was finally proven in the 1950s by isolation of the same virus from lesions of both conditions (238; 239).
In a series of papers from 1907 to 1937, American neurologist James Ramsay Hunt (1872-1937) called attention to a form of cranial herpes zoster that he termed “geniculate neuralgia” (106; 107; 108; 109; 110; 111; 112; 157; 156; 146.) He proposed a concept of viral inflammation of the geniculate ganglion with associated neurologic manifestations, particularly skin eruptions affecting the auricle or external auditory canal and facial nerve palsy.
In 1907 Hunt outlined three groups of cases of herpes zoster (of which he had four personal cases, combined with the 56 he collected from the literature, for a total of 60) (106; 27; 146).
Group 1. Herpes zoster of the auricle and external canal with periauricular pain (Hunt had no cases in this group).
Group 2. Herpes zoster with facial paralysis and periauricular pain, usually with skin lesions of the auricle and external canal, or alternatively of the face, the occiput, or the neck. Hunt attributed this to “pressure of the inflamed (geniculate) ganglion, or in some cases, by a direct extension of the inflammation to the (facial) nerve” (106).
Group 3. Herpes zoster with facial paralysis, periauricular pain, and auditory/vestibular symptoms, again usually with skin lesions of the auricle and external canal, or alternatively of the face, occiput, or neck. Hunt assumed in these cases “that the inflammatory process has extended to the auditory nerve, which is enveloped in the same sheath, and courses in the same canal as the facial nerve” (106).
Several problems are apparent with this classification (146).
(1) What exactly is “Ramsay Hunt syndrome” given that there were three groups of cases and no defining theme? Most subsequent authors have simply considered Ramsay Hunt as herpes zoster of the auricle and external canal with facial paralysis, with or without auditory/vestibular symptoms, ie, a subset of groups 2 and 3 in which the cutaneous lesions are restricted to the auricle or external auditory canal.
(2) If one tries to define Ramsay Hunt syndrome as “herpes zoster oticus” and by that include all cases with herpes zoster of the auricle or external auditory canal, one excludes some of what Hunt included, eg, cases of facial paralysis without skin lesions of the auricle or external canal, but with instead skin lesions of the face, occiput, or neck.
(3) Other groups of cases have subsequently been recognized that do not fit in Hunt’s scheme, but seem as if they should be included, ie, (a) facial nerve paralysis due to varicella-zoster virus but without any apparent skin lesions; and (b) cranial polyneuropathy (including facial nerve paralysis) due to zoster, extending to nerves other than VII and VIII.
(4) Some authors apply Hunt’s classification of cases even when the cases do not strictly meet the characteristics of the groups he described (255).
A modified scheme is presented below for cranial zoster, in which all of Ramsay Hunt’s collected cases could be grouped, as well as subsequently identified groups such as zoster sine herpete and zoster cranial polyneuropathy that includes facial paresis.
Group 1. Herpes zoster skin lesions without neurologic manifestations, involving the head, subcategorized by dermatomal territory (or territories) involved.
Group 2. Herpes zoster cranial neuropathy (or polyneuropathy) without skin lesions, subcategorized by the cranial nerves involved.
Group 3. Herpes zoster cranial neuropathy (or polyneuropathy) with skin lesions, subcategorized by the cranial nerves and dermatomal territories involved.
However, for purposes of simplicity and for consistency with previous publications, in this article herpes zoster oticus will be considered as peripheral facial nerve impairment (motor and/or sensory) due to varicella-zoster virus, with or without associated rash, with or without associated otologic manifestations, and with or without other neurologic complications (including cranial polyneuropathy or meningitis).
Clinical manifestations
Presentation and course
|
• Herpes zoster (“shingles”) typically presents as a vesicular rash with pain and itching in a dermatomal pattern. | |
|
• A pre-eruptive prodrome can include headache, photophobia, and malaise but not typically fever. | |
|
• Herpes zoster oticus is a specific form of herpes zoster that often presents with pre-eruptive (“preherpetic”) pain, allodynia, burning, or itching generally localized to the ear and mastoid region. | |
|
• A small proportion of cases of facial palsy associated with varicella-zoster infection do not have an associated rash (or at least no rash in the expected location in the internal auditory canal or on the tympanic membrane), a condition referred to as “zoster sine herpete”. | |
|
• Otologic complications of herpes zoster oticus include tinnitus, sensorineural hearing loss, hyperacusis (dysacusis), vertigo, nystagmus, and skew deviation (and associated diplopia). | |
|
• Herpes zoster oticus may occur as a cranial polyneuropathy, involving especially cranial nerves VII and VIII but also III, V, VI, IX, X, XI, and XII, and C2-C4 sensory dermatomes. |
Herpes zoster (“shingles”) typically presents as a vesicular rash with pain and itching in a dermatomal pattern. A pre-eruptive prodrome can include headache, photophobia, and malaise, but not typically fever (79).
Herpes zoster oticus is a specific form of herpes zoster that often presents with pre-eruptive (“pre-herpetic”) pain, allodynia, burning, or itching generally localized to the ear and mastoid region (146). An erythematous maculopapular rash progresses to clusters of clear vesicles on an inflamed base; such skin lesions may variably affect the tympanic membrane, external auditory canal, auditory meatus, and less commonly the external ear, adjacent skin of the mastoid process, the mucous membranes of the soft palate (presumably via the greater superficial petrosal nerve), and the anterior two thirds of the tongue (presumably via the chorda tympani nerve) (210).
-
Vesicular eruption of right auricle, external auditory canal, and tympanic membrane in herpes zoster oticus
Vesicular eruption of the right auricle (A), external auditory canal, and tympanic membrane (B) in a 42-year-old woman with herpes zoster oticus, delayed facial nerve palsy, and cranial polyneuropathy. (Source: Al-Ani RM. Ramsa...
-
Vesicles along medial aspect of the antihelix in herpes zoster oticus
Vesicles noted along the medial aspect of the antihelix of the right ear (arrow). (Source: Gillette BT, Heilbronn CM. A rare case of vocal cord paralysis in the setting of Ramsay Hunt syndrome. Cureus 2023;15[3]:e36027. Creativ...
Vesicle fluid quickly changes from clear to purulent. The vesicles crust over after 3 to 5 days. Associated constitutional symptoms can include lymphadenopathy, headache, malaise, and fever. Ultimately the skin lesions heal over 2 to 4 weeks, often leaving residual scarring and pigmentary changes.
Facial palsy may precede, occur simultaneously with, or follow the rash in herpes zoster oticus (04; 129) .
In adults, the rash typically occurs slightly before or around the same time as the facial paresis, whereas in children the rash may appear several days after the onset of facial paresis (49; 95; 129). Facial palsy in herpes zoster oticus can be associated with decreased lacrimation and decreased taste or dysgeusia on the anterior two thirds of the tongue. Facial paresis is usually maximal within 1 week of onset. Increasing severity of paresis is associated with increasing age. Herpes zoster oticus is more likely than Bell palsy to be associated with a complete clinical facial paralysis (200; 02).
A small proportion of cases of facial palsy associated with varicella-zoster infection do not have an associated rash (or at least no rash in the expected location in the internal auditory canal or on the tympanic membrane), a condition referred to as “zoster sine herpete” (210; 187; 63; 65; 66) and a condition long recognized with other forms of herpes zoster (150; 53; 163; 75). Zoster sine herpete is more common in children than adults, particularly in preschool children (183).
Otologic complications of herpes zoster oticus include tinnitus, sensorineural hearing loss, hyperacusis (dysacusis), vertigo, nystagmus, and skew deviation (and associated diplopia) (25; 28; 195; 208; 116; 99; 141; 237; 02; 207; 233; 121; 139; 158; 89; 255; 146).
Abnormal hearing in patients with herpes zoster oticus is associated with otalgia, herpetic rash, and vertigo, but not with the presence or severity of facial paresis (237; 128; 214). Hearing loss is more severe in the high-frequency range (4-8 KHz) than in the low-frequency range (≤ 2 KHz) (128). Audiological findings demonstrate both sensory (ie, cochlear) and neural (ie, retro-cochlear) hearing impairment (01; 237; 255). Hyperacusis is not simply attributable to seventh nerve dysfunction as a result of loss of the stapedial reflex (164), because hyperacusis is also described in herpes zoster oticus patients with an intact stapedial reflex (37; 237); in some cases, hyperacusis may result from damage to inhibitory efferent fibers in the seventh nerve (37). Various patterns of nystagmus including direction-fixed and positional direction-changing nystagmus occur in herpes zoster oticus, likely due to inflammation of the vestibular nerve and inner ear end organs (149). Direction-fixed positional nystagmus is more common than direction-changing positional nystagmus (75% vs. 5%, respectively); direction-changing positional nystagmus may result from an alteration of the specific gravity of the lateral semicircular canal cupula or endolymph due to inflammation in the inner ear membrane (127).
Herpes zoster oticus may occur as a cranial polyneuropathy, involving especially cranial nerves VII and VIII, but also III, V, VI, IX, X, XI, and XII, and C2-C4 sensory dermatomes (47; 51; 31; 17; 163; 69; 181; 02; 16; 224; 46; 74; 219; 245; 180; 89; 117; 105; 132; 184; 191; 213; 217; 06; 212; 88; 215; 221; 251; 193; 196; 05; 08; 154; 77; 216). Cases of sequential involvement of the trigeminal and facial nerves, with lesions on MRI involving the spinal trigeminal nucleus and tract and the facial nerve (105; 184) have raised the possibility of transaxonal spread of varicella-zoster virus between the trigeminal nerve, the facial nerve, and the spinal trigeminal nucleus and tract (105). Intersynaptic spread of reactivated varicella-zoster virus along the reflex pathways of the brainstem has been proposed to explain the development of cranial polyneuropathies in conjunction with herpes zoster oticus (06). Cranial polyneuropathy is more common in adults than children (95).
In unusual cases, atypical cranial nerves or other central nervous system structures may be involved, with manifestations including optic neuropathy, Horner syndrome, trochlear nerve palsy, cerebellar abnormalities, multifocal vasculopathy and posterior circulation strokes, hemiparesis, hemi-hypoesthesia, aseptic meningitis, encephalitis, meningo-rhombencephalitis, and myelitis (119; 125; 31; 23; 19; 159; 104; 131; 186; 57; 58; 124; 199; 154; 77; 194; 03). The basis for some of these symptoms is not clear, and may vary in some cases, including meningeal involvement, demyelinating events, and vasculitic involvement (186; 113). Herpes zoster oticus may follow varicella zoster viral meningitis even in young immunocompetent men (113).
Clinical manifestations of herpes zoster oticus and other forms of herpes zoster are often more severe in adults than children (103; 95; 123).
Recurrent facial palsy due to herpes zoster oticus is rare (126; 211): among 1243 patients seen for facial palsy, four cases had recurrent VZV-related palsy (ie, both the first and second palsies were VZV-related), and all of them initially had zoster sine herpete (126).
Prognosis and complications
The recurrence rate of herpes zoster is approximately 6% (249). Recurrences are significantly more likely among women, those aged at least 60 years at the index episode, those with associated pain of at least 30 days’ duration following the index episode, and immunocompromised individuals (249).
Herpes zoster oticus is more likely than Bell palsy to be associated with a complete clinical facial paralysis and a less complete clinical recovery (200; 02; 74; 250; 213; 30; 70). A shorter time between herpes zoster and the onset of neurologic symptoms appears to be a negative prognostic factor (40).
Vestibular neuritis patients demonstrate a significantly higher vestibulo-ocular reflex gain recovery compared to patients with Ramsay Hunt syndrome (160). In particular, a significantly faster reduction in the latency, velocity, and organization of the compensatory saccades was observed in vestibular neuritis than in patients with Ramsay Hunt syndrome (160).
Facial paresis in herpes zoster oticus completely resolves in about one half to two thirds of patients after incomplete loss of function, usually within about 3 months (97; 49; 181; 95; 213), whereas complete recovery is achieved in only about 10% of patients after complete loss of facial nerve function (49) and in only about 27% of patients with multiple cranial neuropathy associated with herpes zoster oticus (213).
Most of the remaining cases are left with mild residual signs, but about 10% are left with an “unsatisfactory” outcome (97). Factors associated with less complete recovery are more severe impairment (ie, incomplete eye closure, dry eye, and poor results of electroneurography), older age, vertigo, diabetes mellitus, hypertension, and multiple cranial nerve involvement (250; 42; 213; 29; 08). Factors that predict the development of synkinesis following herpes zoster oticus include results of electroneurography, the severity of facial weakness, and the change in weakness over a 1-month period (169).
With prompt treatment with antiviral medication, the outcome of facial palsy in Ramsay Hunt syndrome approximates that of Bell palsy, which emphasizes the importance of recognizing the syndrome and treating it accordingly (122).
The recovery from hearing loss is generally good, although incomplete in some patients (237; 02); however, some authors have reported a poor prognosis for hearing loss (132). Prognostic indicators of poor hearing recovery include advanced age, retro-cochlear hearing loss, hearing loss affecting the speech frequencies (ie, approximately 250 to 8000 Hz), vertigo, and male gender (237). Elderly patients in particular can be disabled by severe and persistent imbalance (02), leading to repeated falls, falls with injury, fear of falling, and impairment in activities of daily living and psychosocial function (35).
Absence of blink reflex and low mean electroneurography value are significantly associated with incomplete recovery of facial paresis (91). An absent blink reflex is more likely to be associated with severe residual facial palsy in Ramsay Hunt syndrome than in Bell palsy (91).
Clinical vignette
Case 1. Ramsay Hunt syndrome (Hunt group 2) (18). An 11-year-old boy complained of 1 week of fever, sore throat, and otalgia. He was diagnosed with otitis media and was started on oral antibiotics. However, he developed a right peripheral facial paresis 1 week later. He was diagnosed with Bell palsy and was started on methylprednisolone. On the second day of treatment with methylprednisolone, painful vesicles developed in the right ear. Audiograms were normal. He was diagnosed with Ramsay Hunt syndrome and started on acyclovir (10 mg/kg/day). The ear lesions resolved within 3 weeks, and the facial paresis resolved within 6 weeks.
Case 2. Ramsay Hunt syndrome (Hunt group 2) (18). A 12-year-old girl complained of 3 days of sore throat, cough, left otalgia, and facial asymmetry. Exam disclosed a left peripheral facial paresis and a vesicular rash in her left ear. There were no cochleovestibular symptoms, and audiograms were normal. She was started on a 5-day course of acyclovir (800 mg/day) and a 14-day course of methylprednisolone (2 mg/kg/day for 1 week, and then 1 mg/kg/day for 1 week). The facial paresis resolved by the end of the first week. Photographs show a right peripheral facial paresis and vesicular lesion in the left auricle.
Case 3. Ramsay Hunt syndrome (Hunt group 3) (18). A 12-year-old boy presented with complaints of left otalgia, vertigo, and vomiting. He developed vesicles in the left auricle and external auditory canal and a left peripheral facial paralysis. His initial audiogram showed a mild to moderately severe left sensorineural hearing loss and normal hearing on the right. He was treated with antiviral and corticosteroid therapy, and in addition, he received an antiemetic and a sedative to control the vestibular symptoms. The pain resolved by day 5, the vesicular rash and vertigo resolved by day 10, and the facial paresis, hearing loss, and subjective tinnitus resolved within the first month. An audiogram after treatment had largely normalized; there was normal hearing to slight sensorineural hearing loss on the left and normal hearing on the right.
Case 4. Ramsay Hunt syndrome (Hunt group 3) (113). A 32-year-old man presented to the emergency room with a 1-week history of persistent headache. On the fourth day of illness, he developed an intermittent fever, and a small vesicular lesion erupted around the right ear with associated mild pain, consistent with shingles. He had a history of chickenpox as a child. At the time of admission, he was severely nauseous.
Neurologic examination revealed subtle neck stiffness. C-reactive protein was elevated at 18.4 mg/L (normal range: 0-5 mg/L), whereas the other blood tests were within the normal range, including a complete blood cell count and an erythrocyte sedimentation rate. Brain MRI was normal. CSF examination revealed a slightly increased intracranial pressure (210 mm CSF), an elevated CSF protein (255.5 mg/dL), lymphocyte-dominant pleocytosis (800/mm3, lymphocytes 90%), and a slightly decreased CSF/serum glucose ratio (47/105 = 0.45). Polymerase chain reaction testing of the CSF confirmed varicella-zoster virus positivity.
He was treated with intravenous acyclovir 10 mg/kg every 8 hours, considering the possibility of varicella-zoster virus meningitis. Antipyretics and analgesics were used to control fever, headache, and pain related to the vesicular lesions around the ear. On the third day of hospitalization, he developed a right peripheral facial palsy. On the eleventh day of hospitalization, he developed a left peripheral vestibulopathy with severe vertigo and tinnitus, with corresponding spontaneous left-beating nystagmus obeying Alexander’s law (ie, greater intensity in the quick-phase direction looking away from the responsible lesion than in the slow-phase direction looking toward the responsible lesion).
Pure tone audiometry showed a high-frequency sensorineural hearing loss in the right ear. A facial nerve conduction study showed nonspecific findings. A blink reflex test revealed absent responses of ipsilateral R1 and R2 and contralateral R2 at stimulation of the right supraorbital nerve.
-
Pure-tone audiometry revealing high-frequency sensorineural hearing loss in Ramsay-Hunt syndrome (1)
Pure-tone audiometry revealing both increased air and bone conduction thresholds without an air-bone gap in the right ear, consistent with high-frequency sensorineural hearing loss. (Source: Hwang YS, Kim YS, Shin BS, Kang HG. ...
-
Nonspecific findings on facial nerve conduction study in Ramsay-Hunt syndrome
A facial nerve conduction study revealed nonspecific findings. NCV = nerve conduction velocity. (Source: Hwang YS, Kim YS, Shin BS, Kang HG. Two cases of Ramsay-Hunt syndrome following varicella zoster viral meningitis in young...
After he developed a peripheral facial palsy, oral prednisolone was administered (50 mg of for 7 days followed by gradual tapering). Acyclovir was continued for a total of 14 days from the day of admission. At discharge on the 20th day of hospitalization, his headache and fever had subsided significantly, but he had persistent facial palsy, dizziness, and tinnitus.
Case 5. Ramsay Hunt syndrome (Hunt group 3) (113). A 43-year-old man presented to the emergency room with a 10-day history of persistent throbbing headache, accompanied by pain in the right ear, and right facial weakness that had developed 6 days after headache onset. The patient had received a 7-day course of antiviral and steroid therapy for suspected shingles, beginning on the third day of the headache onset.
At the time of admission, he complained of vesicles and pain around the right ear, headache, right facial palsy, hypogeusia, dizziness, hearing loss, and tinnitus. He was not febrile (37.9 °C).
Neurologic examination revealed a right peripheral facial palsy. Blood tests were normal, including CBC, ESR, and CRP. An abnormal enhancing lesion was observed in the right facial nerve on a brain MRI with contrast, suggestive of right facial neuritis.
Abnormal enhancing lesion in right facial nerve in Ramsay-Hunt syndrome
Contrast‐enhanced T1‐weighted MRI of the brain showing enhancement in the right facial nerve (white arrows). (Source: Hwang YS, Kim YS, Shin BS, Kang HG. Two cases of Ramsay-Hunt syndrome following varicella zoster viral mening...
CSF examination revealed a normal opening pressure (80 mm CSF), lymphocyte-dominant pleocytosis (53/mm3, lymphocytes 98%), slightly increased CSF protein (61.0 mg/dL), and a normal CSF/serum glucose ratio (70/117 = 0.60). A CSF PCR test confirmed varicella-zoster virus positivity.
Pure tone audiometry showed a sensorineural hearing loss with mild loss at 500 Hz and sloping mild to moderate loss above 2 KHz. A facial nerve conduction study revealed prolonged terminal latency and decreased CMAP amplitude of the right facial nerve upon its direct stimulation. A blink reflex test revealed absent responses of ipsilateral R1 and R2 and contralateral R2 at stimulation of the right supraorbital nerve.
-
Pure-tone audiometry revealing high-frequency sensorineural hearing loss in Ramsay-Hunt syndrome (2)
Pure-tone audiometry revealing both increased air and bone conduction thresholds without an air-bone gap in the right ear, consistent with predominantly high-frequency sensorineural hearing loss. (Source: Hwang YS, Kim YS, Shin...
He was treated with intravenous acyclovir (10 mg/kg every 8 hours) or oral corticosteroids for 7 days (considering the antiviral treatment from a separate facility). The accompanying pain was treated symptomatically. At discharge, the patient’s headache and dizziness had subsided, but he had persistent facial palsy, auditory symptoms, and pain around his ear.
Case 6. Ramsay Hunt syndrome (Hunt group 3) (211). A 53-year-old woman presented with a 6-day history of left-sided otalgia associated with a vesicular rash involving the left pinna and external auditory canal, with subsequent blistering. She also reported reduced left-sided hearing. Two days later she developed left-sided facial weakness and was unable to close her left eyelid. This occurred on a background of recent chemotherapy for stage IV high-grade serous ovarian cancer, with lung, spleen, nodal, umbilical, and peritoneal metastases; she had completed five of six cycles of chemotherapy (carboplatin, paclitaxel, and bevacizumab) one week prior to symptom onset.
Examination revealed an extensive vesicular eruption involving the left pinna and external auditory canal, with an associated necrotic focus in the conchal bowl.
Extensive vesicular eruption involving the left pinna and external auditory canal
Extensive vesicular eruption involving the left pinna and external auditory canal, with an associated necrotic focus in the conchal bowl and subsequent blistering. (Source: Sheik-Ali S, Jiang Y, Nasef H, Sproson E, Tuohy O. Bil...
Weber test lateralized to the right ear and Rinne test was positive on the left, indicating left-sided sensorineural hearing loss. She had a left-sided peripheral facial nerve palsy (House-Brackmann grade IV).
Swabs from the left external auditory canal were positive for varicella zoster virus (VZV) by polymerase chain reaction (PCR). Serum Borrelia burgdorferi tests were negative for Lyme disease. HIV screening to exclude other immunosuppressant conditions was negative.
High-resolution CT of her petrous bones with contrast demonstrated subcutaneous thickening around the left external acoustic meatus without focal collection. MRI with gadolinium contrast of the head/internal auditory canals demonstrated asymmetrical enhancement of the tympanic and mastoid segments of the left facial nerve and both internal auditory canals.
She was treated with oral prednisone (60 mg/day [1 mg/kg] for 14 days) and intravenous acyclovir (400 mg 5 times per day for 14 days). In addition, she received intravenous tazocin (piperacillin/tazobactam), oral ciprofloxacin, and topical gentamicin 0.3% and hydrocortisone acetate drops. For eye protection, she was treated with artificial tears, lubricants, taping, and facial nerve rehabilitation exercises.
Two weeks after presentation, she developed a new right-sided peripheral facial palsy (House–Brackmann grade IV), so collectively a sequential, bilateral facial palsy. Pure tone audiometry revealed a mild-moderate right sensorineural hearing loss.
|{diagram3.jpg}{caption:Pure tone audiogram revealing sensorineural hearing loss}{label:Pure tone audiometry revealed mild-moderate sensorineural hearing loss of the right ear. (Source: Sheik-Ali S, Jiang Y, Nasef H, Sproson E, Tuohy O. Bilateral sequential Ramsay Hunt syndrome in an immunocompromised adult: a rare entity. Ann R Coll Surg Engl 2024; 106[2]:197-9 Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)}|
Repeat MRI of the head and internal auditory canals demonstrated prominent bilateral cochlear and facial nerve bundles within the internal auditory canals. Given her metastatic ovarian cancer, lumbar puncture was performed to exclude leptomeningeal carcinomatosis; CSF cytology did not demonstrate any malignant cells. Given (1) negative CSF cytology; (2) lack of evidence of progression of her underlying cancer on a recent surveillance CT scan of the neck, chest and abdomen; and (3) decreasing CA-125 (cancer antigen 125) levels, her symptom progression and investigations were attributed to bilateral, sequential Ramsay Hunt syndrome.
Subsequently, the vesicular rash involving the left pinna resolved, but there was incomplete recovery of her bilateral facial palsy (House-Brackmann grade III).
Biological basis
|
• Herpes zoster (“shingles”) is caused by the varicella-zoster virus, a member of the alpha subfamily of Herpesviridae. | |
|
• Impaired cell-mediated immunity is an important factor in reactivation of varicella-zoster virus and development of clinical herpes zoster. |
Etiology and pathogenesis
Herpes zoster (“shingles”) is caused by the varicella-zoster virus, a member of the alpha subfamily of Herpesviridae. Varicella-zoster virus is an enveloped DNA virus, whose genome consists of a linear double-stranded molecule of DNA. Primary infection with varicella-zoster virus causes chickenpox, an acute, generally mild infection in children. During the primary infection, the virus establishes latency within sensory ganglia (240). Later reactivation of the virus results in herpes zoster or “shingles.”
Humoral immunity to varicella-zoster virus is not important in preventing reactivation. Antibodies have little or no role in preventing virus reactivation and development of clinical herpes zoster: (1) herpes zoster is observed in patients with positive varicella-zoster virus antibodies prior to the development of zoster; (2) varicella-zoster virus antibodies increase quickly with development of clinical herpes zoster; (3) patients with disseminated zoster have high antibody titers; (4) children with agammaglobulinemia are not at increased risk to develop herpes zoster; and (5) passive immunization with high-titered immunoglobulin neither prevents nor helps treat herpes zoster (71).
In contrast, impaired cell-mediated immunity is an important factor in reactivation of varicella-zoster virus and development of clinical herpes zoster (71; 114; 15; 90). Varicella-zoster virus-specific T cells are thought to be critical for maintaining the virus-host equilibrium and preventing herpes zoster. This is consistent with known risk factors for herpes zoster including leukemia and lymphoma, bone marrow transplant, and HIV infection. Waning of the cell-mediated immune response to varicella-zoster virus with age may help explain the marked increase in zoster with age (71).
Other factors in addition to impaired cell-mediated immunity must also be involved in the development of herpes zoster because most individuals with impaired cell-mediated immunity (and a history of chickenpox) do not develop clinical herpes zoster, and some apparently healthy children and young adults occasionally do get herpes zoster (71; 123). Indeed, most children who develop herpes zoster, even with complications such as herpes zoster oticus, are immunocompetent (84).
In 1900, Head and Campbell established that the pathologic changes of herpes zoster were typically limited to a single dorsal root ganglion or to the sensory ganglion of a cranial nerve and the corresponding nerve root (96). They corroborated earlier findings of acute inflammation, blood extravasation, and destruction of neural elements within sensory ganglia in acute cases.
Unfortunately, in Hunt’s only postmortem study, the geniculate ganglion was lost and not available for examination (106; 27). Subsequent studies by Denny-Brown and Adams did not support the concept of inflammation or degeneration of the geniculate ganglion as the basis of the clinical manifestations in herpes zoster oticus (47). Indeed, the geniculate ganglion was apparently spared, and instead, there was a necrotizing ganglionitis of the second cervical dorsal root ganglion and inflammatory changes in the facial nerve distal to the ganglion.
Subsequent pathologic studies have demonstrated variable perineural, intraneural, and perivascular lymphocytic infiltration of the facial nerve, and in some cases the chorda tympani, auditory, and vestibular nerves, the modiolus and organ or Corti in the cochlea, and the skin of the external auditory meatus (87; 25; 253). Although the geniculate ganglion may show scattered lymphocytic infiltration, most of the neurons in the ganglion are well preserved in herpes zoster oticus (87; 25; 253). None of the existing pathologic studies support Hunt’s concept of extensive damage to the geniculate ganglion as the basis for herpes zoster oticus (47; 87; 25; 253). Grossly pronounced swelling of the facial nerve may be evident at surgery for as long as 4 months following herpes zoster oticus (101).
Studies have demonstrated varicella-zoster virus DNA in the geniculate ganglia of patients with herpes zoster oticus (67; 236; 68; 235; 223). Varicella-zoster virus DNA is present not only in neurons but also in perineuronal satellite cells and non-neuronal cells of latently infected ganglia (74). Varicella-zoster virus DNA may also be present in the auditory and vestibular primary afferent ganglia, and in the facial nerve sheath, CSF, middle ear mucosa, and vesicles on the auricles or oral cavity (236; 235; 173; 185). Different patterns of development of eighth cranial nerve dysfunction can be caused by progression of neuritis or labyrinthitis after varicella-zoster virus reactivation (185). Latent varicella-zoster virus is not integrated into the human chromosome; instead, it may exist in a circular or end-to-end arrangement (38).
MRI examination of herpes zoster oticus 3D-Fluid Attenuated Inversion Recovery (3D-FLAIR) and T1 volume interpolated body examination (T1VIBE) sequences with delayed gadolinium enhancement showed that neurologic damage in herpes zoster oticus can be manifested as labyrinthitis, vestibulocochlear neuritis, and facial neuritis (93).
Epidemiology
|
• Varicella (chickenpox) is usually an illness of childhood that results from primary infection with varicella-zoster virus and is characterized by a febrile, pruritic, maculopapular vesicular rash. | |
|
• Following chickenpox, varicella-zoster virus remains latent in human nerve tissue and reactivates in about 15% of infected people over their lifetimes, resulting in herpes zoster (“shingles”). | |
|
• Risk factors for zoster and herpes zoster oticus in adults include increasing age, bone marrow and organ transplants, lymphoma, HIV infection, treatment of AIDS with protease inhibitors, and systemic lupus erythematosus. | |
|
• Varicella-zoster vaccination can prevent or reduce the occurrence of chickenpox, herpes zoster, and associated complications, including herpes zoster oticus, among those immunized. |
Varicella (chickenpox) is usually an illness of childhood that results from primary infection with varicella-zoster virus and is characterized by a febrile, pruritic, maculopapular vesicular rash. The vesicles evolve into noninfectious dried crusts over 5 to 6 days. Varicella is highly infectious, with secondary infection rates in susceptible household contacts of two thirds or greater. Transmission occurs from person-to-person by direct contact or by airborne spread of respiratory secretions. The incubation period is usually about 2 weeks but ranges from 10 to 21 days. Humans are the only source of infection. The vast majority of patients (approximately 90%) with chickenpox are less than 15 years old, and there is a marked winter-spring seasonal pattern (153).
Following chickenpox, varicella-zoster virus remains latent in human nerve tissue and reactivates in about 15% of infected people over their lifetimes, resulting in herpes zoster (“shingles”). Approximately two thirds of patients with herpes zoster (including herpes zoster oticus) are 65 years of age or older and there is no seasonal pattern (153). Both the incidence and severity of herpes zoster increase sharply with age (86; 55). An initial episode of herpes zoster does not apparently protect against or significantly increase the risk of a subsequent episode (103).
The absolute risk of Ramsay Hunt syndrome within 3 months of zoster diagnosis was 0.01% (95% CI 0.0- 0.01) (59).
Herpes zoster oticus is rare in children under 6 years of age (86; 24; 133; 95; 136) but is an important and often unrecognized cause of acute peripheral facial paralysis in children between 6 and 15 years of age (64; 18). Risk factors for zoster and herpes zoster oticus in children include chickenpox during infancy, childhood leukemia, and childhood HIV infection (86; 95; 175; 167).
Risk factors for zoster and herpes zoster oticus in adults include increasing age, bone marrow and organ transplants, lymphoma, HIV infection, treatment of AIDS with protease inhibitors, treatment of advanced non-small cell lung cancer with immune checkpoint inhibitor, and systemic lupus erythematosus (197; 155; 206; 176; 241; 07; 165; 54; 161; 153; 175; 55; 167; 79; 203). There is no significantly increased risk of a subsequent diagnosis of malignancy following the onset of herpes zoster and, therefore, there is little evidence to support an aggressive search for malignancy in patients diagnosed with herpes zoster (198; 60; 86; 79), although some data suggest that the sites of primary tumor or local radiotherapy may predispose to development of zoster in that specific location (202). Although herpes zoster is associated with HIV infection, herpes zoster is apparently unrelated to CD4 cell count, period from seroconversion, viral load, or rate of disease progression (including progression to AIDS) (78; 07; 165; 161; 167).
The live-attenuated varicella vaccine (Varivax) was licensed by the United States Food and Drug Administration in 1995. Varicella-zoster vaccination can prevent or reduce the occurrence of chickenpox, herpes zoster, and associated complications, including herpes zoster oticus, among those immunized (10; 189; 11; 33; 12; 13; 95; 209; 80; 231; 252). As a result of introduction of this vaccine, there has been a dramatic decline in the incidence of varicella in surveillance areas with moderate vaccine coverage (209; 80; 252). However, although the incidence of varicella decreased dramatically as varicella vaccine coverage in children increased, the incidence of herpes zoster increased (252). Although several potential explanations are possible, it seems likely that the observed increase in herpes zoster infection is a result of a loss of “immunologic boosting” (including loss of exposure to wild-type varicella-zoster virus) for those previously infected with varicella-zoster (80). This loss of immunologic boosting would allow a waning of cell-mediated immunity and would lead to a relative increase in herpes zoster incidence in the population.
Prevention
|
• Varicella-zoster vaccination can prevent or reduce the occurrence of chickenpox, herpes zoster, and associated complications, including herpes zoster oticus, among those immunized. | |
|
• Routine (preexposure) varicella-zoster vaccination is recommended for susceptible children aged 12 months to 13 years and is also desirable for susceptible adolescents and adults. | |
|
• Varicella vaccine is also recommended for susceptible people following exposure to varicella because if administered within 72 hours, and possibly up to 120 hours, it can prevent or attenuate clinical disease. | |
|
• Varicella-zoster vaccine is contraindicated in patients with an allergy to any of the vaccine components (including neomycin or gelatin), during pregnancy, in adults (and some children) with HIV infection, or in children or adults with severe intercurrent illness, leukemia, lymphoma, metastatic cancer, or immunosuppression due to corticosteroids, other immunosuppressive medications, or radiation. | |
|
• Varicella-zoster virus infection can cause serious infection in adult women (particularly pneumonia), is teratogenic, and can produce a life-threatening illness in newborns; therefore, women of childbearing age should be questioned about a history of chickenpox or varicella-zoster virus vaccination before conception and also during their first prenatal visit. | |
|
• Secondary prevention of herpes zoster is now possible for older adults previously infected with chickenpox. | |
|
• The adjuvanted, recombinant varicella-zoster virus subunit vaccine (Shingrix) was approved by the U.S. Food and Drug Administration in 2017. The vaccine is administered in two intramuscular doses of 0.5 ml given 2 to 6 months apart. |
The live-attenuated varicella vaccine (Varivax) was licensed by the United States Food and Drug Administration in 1995. Varicella-zoster vaccination can prevent or reduce the occurrence of chickenpox, herpes zoster, and associated complications, including herpes zoster oticus, among those immunized (10; 189; 11; 33; 12; 13; 95; 209; 80; 231; 252).
Routine (pre-exposure) varicella-zoster vaccination is recommended for susceptible children aged 12 months to 13 years and is also desirable for susceptible adolescents and adults (11). Pre-exposure varicella-zoster vaccination is also particularly recommended for all adolescents and adults who do not have a reliable clinical history of chickenpox, or serologic evidence of varicella-zoster virus infection, and who are at high risk of exposure or transmission (232). This includes healthcare workers (particularly those who have close contact with patients at high risk of serious complications), residents and staff in institutional settings, family contacts of immunocompromised people, and women of childbearing age who are not pregnant and not planning to become pregnant in the next 4 weeks (11). Susceptible patients 13 years of age or older should receive two doses of vaccine, given at least 4 weeks apart.
Varicella vaccine is also recommended for susceptible people following exposure to varicella because if administered within 72 hours, and possibly up to 120 hours, it can prevent or attenuate clinical disease. Post-exposure vaccination should be considered particularly in health care settings and households. Additional considerations for prevention in at-risk people exposed to varicella-zoster virus include passive immunization with varicella-zoster immune globulin and in some cases pharmacologic prophylaxis with acyclovir (10; 11; 12; 13). Varicella-zoster immune globulin is a hyperimmune globulin prepared from healthy volunteer blood donors who are found to have high antibody titers to varicella-zoster virus.
Varicella-zoster vaccine is contraindicated in patients with an allergy to any of the vaccine components (including neomycin or gelatin), during pregnancy, in adults (and some children) with HIV infection, or in children or adults with severe intercurrent illness, leukemia, lymphoma, metastatic cancer, or immunosuppression due to corticosteroids, other immunosuppressive medications, or radiation (11). Varicella-zoster virus vaccine should not be given within 5 months following administration of blood, plasma, immunoglobulins, or varicella-zoster immune globulin. Salicylates should be avoided for 6 weeks following varicella-zoster virus vaccination because of the association between aspirin use and Reye syndrome following varicella.
Varicella-zoster virus infection can cause serious infection in adult women (particularly pneumonia), is teratogenic, and can produce a life-threatening illness in newborns (33). Therefore, women of childbearing age should be questioned about a history of chickenpox or varicella-zoster virus vaccination before conception and also during their first prenatal visit (33). If there is a question about their immunity to varicella-zoster virus, they should be offered serologic testing and vaccination if indicated based on the testing (11; 33). Although a test-then-vaccinate strategy is more cost-effective, testing is not required, and the vaccine is well tolerated in people who are already immune. Vaccine virus transmission to a susceptible contact can occur only if the vaccine has a rash; this risk is low in healthy individuals.
Varicella-zoster virus infection can also be associated with serious complications in immunocompromised individuals, older adults, and young infants. Passive immunization with varicella-zoster immune globulin early in the incubation period can prevent or attenuate varicella-zoster virus infections in susceptible contacts at high risk of infection (eg, young infants, immunocompromised individuals, and older adults with no history or questionable history of chickenpox) (182; 12).
Varicella-zoster virus vaccine is much safer than getting chickenpox. Side effects of varicella-zoster virus vaccine are generally mild and include soreness or swelling at the injection site, fever, or mild rash up to 1 month after vaccination. About 3% of adults develop a localized varicella rash at the injection site (median of two lesions), and about 6% develop a mild generalized rash (median of five lesions, not all at the injection site). The risk of any rash is much lower (less than 1%) after the second dose of vaccine. The rash may be atypical, with macules or papules rather than vesicles. Less common problems include febrile seizures and rarely pneumonia. Healthcare workers who develop a rash should be evaluated at their employer’s occupational health service and furloughed until the rash resolves (typically in 1 to 2 days) to prevent iatrogenic transmission.
Varicella-zoster immune globulin is indicated following exposure to varicella or herpes zoster for people at high risk of developing severe disease and those who are not eligible for vaccination: (1) susceptible pregnant women; (2) newborns whose mothers have chickenpox (or rarely herpes zoster) 5 days before through 2 days after delivery; (3) hospitalized premature infants more than 28 weeks’ gestation, whose mother had no history of varicella; (4) hospitalized premature infants less than 28 weeks or less than 1000 g (regardless of the mother’s immune status or maternal history); (5) children with leukemia or lymphoma who have not been vaccinated; (6) people with HIV/AIDS or other cell-mediated immunodeficiency, including people receiving high-dose systemic steroids or other drugs that suppress the immune system. Varicella-zoster immune globulin is most effective in preventing varicella infection if given within 96 hours of varicella-zoster virus exposure.
In particular, if exposure occurs during pregnancy, the mother can be reassured as to their protection if they have a history of chickenpox. Otherwise (ie, if there is no prior history of chickenpox or the history is uncertain), varicella-zoster immune globulin should be administered if within 10 days of exposure and preferably within 96 hours to try to prevent maternal infection (33; 98; 168). The live-virus vaccine should not be administered during pregnancy, although cases of inadvertent administration continue to occur instead of the intended varicella-zoster immune globulin (243). Oral acyclovir should be considered for susceptible pregnant women who did not receive varicella-zoster immune globulin or who have risk factors for severe disease, and intravenous acyclovir should be administered to pregnant women who develop complicated varicella at any stage of pregnancy (98). Infants whose mothers develop varicella-zoster virus infection peripartum should be treated with varicella-zoster immune globulin (ie, if the onset was from 7 days prior up to 28 days after delivery) and acyclovir (if the onset was from 4 days before to 2 days after delivery) (98; 168).
Secondary prevention of herpes zoster is now possible for older adults previously infected with chickenpox. In 2005, Oxman and colleagues reported the results of the Shingles Prevention Study, a large, randomized, double-blind, placebo-controlled trial of a high-potency, live-attenuated varicella-zoster vaccine (190; 15; 72). More than 38,000 adults over 60 years of age were enrolled. The varicella-zoster vaccine markedly reduced the morbidity from both herpes zoster and postherpetic neuralgia among older adults. After a median of more than 3 years of surveillance, the use of the varicella-zoster vaccine reduced the incidence of herpes zoster by 51%, the burden of illness due to herpes zoster by 61%, and the incidence of postherpetic neuralgia by 67%. Local reactions at the vaccination site were generally mild, and the vaccine had low rates of serious adverse events, hospitalization, and death. The U.S. Food and Drug Administration licensed this live-attenuated zoster vaccine (Zostavax) in 2006, for use in people aged 60 years and older (U.S. Food and Drug Administration 2006), and in March 2011 the FDA expanded approval of a live-attenuated zoster vaccine (Zostavax) to adults aged 50 to 59 years (32). The live zoster vaccine has a minimum potency at least 14 times greater than the minimum potency of the vaccine licensed to prevent varicella, because a much higher potency is needed to produce a significant increase in cell-mediated immunity to varicella-zoster virus in older adults (190). The vaccine is administered as a single subcutaneous injection, preferably in the upper arm.
In 2012, Schmader and colleagues reported a randomized, double-blind, placebo-controlled trial of the live, attenuated zoster vaccine (Zostavax) among 22,439 subjects aged 50 to 59 years (205). The study was conducted at 105 sites in North America and Europe. In subjects aged 50 to 59 years, the live, attenuated zoster vaccine (Zostavax) significantly reduced the incidence of herpes zoster, with vaccine efficacy at preventing herpes zoster estimated at 70%. The vaccine was well tolerated, with adverse effects primarily limited to injection site reactions and headaches. On March 24, 2011, on the basis of prepublication results of this study, the U.S. Food and Drug Administration expanded the licensing of this live, attenuated zoster vaccine (Zostavax) for use in people aged 50 years and older (U.S. Food and Drug Administration 2017).
Consequently, the presently licensed live, attenuated zoster vaccine (Zostavax) reduces the incidence of herpes zoster by 70% among those aged 50 to 59 years, by 64% among those aged 60 to 69 years, and by 38% among those aged 70 years and older (190; 205; 39). The vaccine reduces the incidence of postherpetic neuralgia by 66% among those aged 60 to 69 years, and by 67% among those aged 70 years and older (190; 39).
The long-term persistence of efficacy for the live, attenuated zoster vaccine (Zostavax) was reported in 2015, and this study showed that efficacy declines significantly over time (170). Among 6867 participants who were enrolled from the original Shingles Prevention Study into the Long-Term Persistence Substudy, estimated vaccine efficacy decreased from 61% to 37% for the herpes zoster burden of illness, from 67% to 35% for incidence of postherpetic neuralgia, and from 51% to 21% for incidence of herpes zoster. Efficacy declined for all three outcome measures from 7 through 11 years after vaccination. The vaccine significantly reduced the burden of illness caused by herpes zoster for 10 years after vaccination, but significantly reduced the incidence of herpes zoster for only 8 years after vaccination. The safety and efficacy of administering a booster dose of the live, attenuated zoster vaccine 10 or more years after the initial dose is not yet clear (39).
Given the limited efficacy and persistence of the live, attenuated zoster vaccine (Zostavax), vaccine development has continued. In 2015, Lal and colleagues reported a randomized, double-blind, placebo-controlled, phase 3 trial of an adjuvanted herpes zoster subunit vaccine in older adults (aged 50 years and older) that had been conducted in 18 countries (39; 145). The recombinant vaccine contains a surface varicella-zoster virus glycoprotein E (gE) antigen obtained from cultured cells and a liposomal adjuvant (AS01B) to enhance the immune response (44; 14; 22). Participants received two intramuscular doses of the vaccine or placebo over an interval of 2 months. During a mean follow-up of 32.2 years, overall vaccine efficacy against herpes zoster was 97%, and this estimate was remarkably uniform at between 97% to 98% for those aged 50 to 59 years, 60 to 69 years, and 70 years and older. Injection site and systemic reactions were more common in the vaccine group, but the proportions who had serious adverse events, possible immune-mediated disease (of concern given the adjuvants), or who died were similar in the vaccine and control groups.
In 2016, Cunningham and colleagues reported a second trial of the subunit vaccine (44; 179). This trial, conducted concurrently with the previously reported trial at the same sites, evaluated the safety and efficacy of the subunit vaccine in adults aged 70 years and older. During a mean follow-up of 3.7 years, vaccine efficacy against herpes zoster was 90%, and was similar in those aged 70 to 79 years and in those aged 8 years and older. Injection site and systemic reactions were more common in the vaccine group, but the proportions who had serious adverse events, possible immune-mediated disease (of concern given the adjuvants), or who died were again similar in the vaccine and control groups.
In pooled analyses of the two trials of the subunit vaccine for those aged 70 years and older, vaccine efficacy against herpes zoster was 91% and against postherpetic neuralgia was 89% (44). The subunit vaccine appears to be more effective than the live, attenuated vaccine, especially in those over 70 years of age (190; 39; 145; 44; 179). It may also prove to be useful in those with impaired cell-mediated immunity, for whom the live, attenuated vaccine is contraindicated (39): such individuals include those with hematopoietic-cell transplantation, those with HIV infection and low CD4+ cell counts, or those receiving potent immunosuppressive medications. Whether the subunit vaccine will elicit a sufficiently protective immune response in those with impaired cell-mediated immunity remains to be proven (39).
The adjuvanted, recombinant varicella-zoster virus subunit vaccine (Shingrix) was approved by the U.S. Food and Drug Administration on October 20, 2017 (85). The vaccine is administered in two intramuscular doses of 0.5 ml given 2 to 6 months apart. Based on immunogenicity data, the protective effect of recombinant varicella-zoster virus vaccine (Shingrix) is expected to persist for at least 9 years after vaccination (14). The efficacy of recombinant varicella-zoster virus vaccine (Shingrix) in persons who receive only one dose is not known. The safety and efficacy of administering the subunit zoster vaccine among those who had previously received the live, attenuated vaccine have not been tested (39), nor has there been a head-to-head trial of the live-attenuated varicella-zoster virus vaccine (Zostavax) and the recombinant varicella-zoster virus vaccine (Shingrix). The Advisory Committee on Immunization Practices now recommends recombinant varicella-zoster virus vaccine (Shingrix) over live-attenuated varicella-zoster virus vaccine (Zostavax) for herpes zoster prevention and, furthermore, recommends that healthy adults aged 50 years or older, including those who have already received live-attenuated varicella-zoster virus vaccine (Zostavax), be vaccinated with two doses of recombinant varicella-zoster virus vaccine (Shingrix) (2 to 6 months apart).
Differential diagnosis
Acute facial palsy without the pathognomonic vesicles is generally diagnosed as Bell palsy (162; 95; 219). In children, particularly, the appearance of vesicles is often delayed (95), leading to misdiagnosis of Bell palsy in patients with herpes zoster oticus. In adults, herpetic cranial polyneuritis may occasionally mimic brainstem infarction (21). In an elderly man, herpes zoster oticus was originally misdiagnosed as malignant otitis externa (43). Several clinical features associated with clinical peripheral facial paresis should increase diagnostic suspicion of herpes zoster oticus: complete clinical facial paralysis; severe otalgia; sensorineural hearing loss; or a reddish ear (even without a herpetic rash) (02).
Diagnostic workup
|
• Herpes zoster oticus can usually be diagnosed clinically. The situation is more complicated in the absence of a rash or in the presence of other neurologic manifestations (eg, hemiparesis, cranial polyneuropathy, etc.). | |
|
• Laboratory diagnosis or varicella-zoster virus infection can include (1) positive serologic test for varicella-zoster immunoglobulin M (IgM) antibody; (2) isolation of varicella-zoster virus from vesicles (or possibly blood or CSF in immunocompromised patients), although varicella-zoster virus is labile and difficult to recover from swabs of cutaneous lesions; (3) demonstration of varicella-zoster virus antigen by direct fluorescent antibody testing in material swabbed from the base of a freshly unroofed fluid-filled vesicle or in lesion crusts; (4) detection of varicella-zoster virus DNA by polymerase chain reaction tests on clinical specimens from cutaneous lesions, tear fluid or saliva, blood monocytes, or CSF; or (5) a significant rise in varicella immunoglobulin G (IgG) antibody level in serum. | |
|
• Patients with herpes zoster oticus typically have high signals in the inner ear on precontrast 3D-FLAIR MRI, a finding that is rare in patients diagnosed with Bell palsy (peripheral facial paresis without vesicular rash or audiovestibular symptoms). |
Herpes zoster oticus can usually be diagnosed clinically. The situation is more complicated in the absence of a rash, or in the presence of other neurologic manifestations (eg, hemiparesis, cranial polyneuropathy, etc.). Associated facial swelling in some cases can suggest bacterial odontogenic infection and facial cellulitis (118).
In high-risk settings (eg, hospitals, nursing homes, prisons), rapid case identification is important to prevent susceptible people at high risk (eg, immunocompromised or pregnant individuals) from developing serious complications of varicella-zoster virus infection.
Laboratory testing. Laboratory testing for varicella-zoster virus in herpes zoster oticus is not routinely required but can be helpful in selected cases to confirm the diagnosis (eg, zoster sine herpete) (73; 74; 219). Laboratory diagnosis or varicella-zoster virus infection can include (1) positive serologic test for varicella-zoster immunoglobulin M (IgM) antibody (222); (2) isolation of varicella-zoster virus from vesicles (or possibly blood or CSF in immunocompromised patients), although varicella-zoster virus is labile and difficult to recover from swabs of cutaneous lesions (79; 41); (3) demonstration of varicella-zoster virus antigen by direct fluorescent antibody testing in material swabbed from the base of a freshly unroofed fluid-filled vesicle or in lesion crusts; (4) detection of varicella-zoster virus DNA by polymerase chain reaction tests on clinical specimens from cutaneous lesions (172), tear fluid or saliva (100; 144), blood monocytes (222; 74), or CSF (73; 74; 41); or (5) a significant rise in varicella immunoglobulin G (IgG) antibody level in serum (222). Because viral proteins persist after the virus is no longer replicating, direct fluorescent antibody tests may be positive when viral cultures are negative. Virus isolation should be attempted in cases with severe disease, especially in immunocompromised cases. Virus can usually be cultured from zoster lesions for 7 days or longer, and results may be available within 2 to 3 days.
Spinal fluid examination. CSF, though rarely examined in patients with herpes zoster oticus, may be normal (253), or may show lymphocytosis and occasionally a modest elevation of protein concentration (47; 25; 137). Almost two thirds of patients with herpes zoster oticus have a modest CSF pleocytosis (mean 84 cells/mm3; range 7 to 250 cells/mm3) (137). Varicella-zoster virus IgM antibody and DNA (ie, by polymerase chain reaction techniques) can be demonstrated in CSF (73; 74; 82), which can be diagnostically helpful in some cases of zoster sine herpete. Variations in commercial, real-time polymerase chain reaction tests can impact the sensitivity of diagnostic testing (246).
Video head impulse testing and vestibular evoked myogenic potentials. Video head impulse test (vHIT) and vestibular evoked myogenic potential (VEMP) can be used for vestibular analysis of peripheral vestibular organs: in herpes zoster oticus, (1) the lateral semicircular canal was the most impaired semicircular canal, followed by the anterior and posterior semicircular canals, and (2) the utricle was more impaired than the saccule (102).
Neuroimaging. Although not as sensitive as MRI, computed tomography may show abnormalities including abnormal enhancement (77).
Enhancement in medial right temporal lobe due to varicella-zoster virus (CT)
Transverse CT image of the soft tissue head demonstrating faint enhancement along the medial right temporal lobe, measuring about 1.5 × 1.18 cm (arrow). The differential includes reactive or infectious processes, low-grade glio...
The membranous labyrinth normally appears on T1-weighted MRI images as a nonenhancing intermediate-signal-intensity structure surrounded by the low-signal intensity of the petrous temporal bone (52). In approximately 50% to 70% of cases with facial nerve palsy due to the varicella-zoster virus, variable degrees of enhancement of the seventh and eighth cranial nerves, the labyrinth, the geniculate ganglion, and the internal and external auditory canals enhance on postcontrast MRI using gadolinium (143; 188; 138; 151; 201; 52; 220; 242; 120; 140; 26; 20; 204; 218; 105; 184; 148; 93). In addition, about half of patients with herpes zoster oticus show signal abnormalities in the vestibular nuclei, which lie in multiple vascular territories, indicating that herpes zoster oticus may at least in part reflect vestibular neuritis, as opposed to a pure neuritis (247).
Enhancement of distal right internal auditory canal due to varicella-zoster virus (MRI)
Brain magnetic resonance image showing increased enhancement in the distal right internal auditory canal (arrow). (Source: Chou CC, Lo YT, Su HC, Chang CM. Fear of falling as a potential complication of Ramsay Hunt syndrome in ...
In rare cases, there may also be enhancement of the pontine facial nerve nucleus (204), as well as the internal auditory canal dura and sometimes the parotid gland (34).
Patients with herpes zoster oticus typically have high signals in the inner ear on precontrast 3D-FLAIR MRI, a finding that is rare in patients diagnosed with Bell palsy (peripheral facial paresis without vesicular rash or audiovestibular symptoms) (178; 36; 142). Precontrast hyperintensity on 3D-FLAIR MRI is associated with the presence of vertigo and severity of hearing impairment but not with clinical outcome (36). Audio-vestibular deficits are well correlated with increased signal intensity of the inner ear end organs on 3D-FLAIR images 4 hours post-contrast (148). Comparison of 3D-FAIR and T1 volume interpolated body examination (T1VIBE) sequences with 4.5 hours delay after intravenous gadolinium injection in four patients with herpes zoster oticus showed that a 3D-FLAIR sequence with a delay of 4.5 hours post intravenous gadolinium injection was more likely to show whether the inner ear labyrinth barrier permeability increased (93). The lateral semicircular canal shows high signal intensity on 3D-FLAIR images 4 hours post-contrast in 75% of patients with abnormal canal paresis on bithermal caloric testing (148). Although the cochlea shows high signal intensity on 3D-FLAIR images 4 hours post-contrast in 75% of patients with hearing loss, the vestibulo-cochlear nerve shows enhancement in post-contrast T1-weighted images in only 33% of patients with hearing loss (148).
-
Internal auditory canal of a patient with herpes zoster oticus (MRI) (1)
Internal auditory canal MRI image of a patient with herpes zoster oticus. The post-contrast 3D-FLAIR MRI shows high-signal intensities of cochlea (long arrow), posterior semicircular canal, lateral semicircular canal (large arr...
-
Internal auditory canal of a patient with herpes zoster oticus (MRI) (2)
Internal auditory canal MRI image of a patient with herpes zoster oticus. The post-contrast 3D T1-weighted image shows that the labyrinthine segment of the left facial nerve is enhanced (arrow). (Source: Lee J, Choi JW, Kim CH....
-
Internal auditory canal of a patient with herpes zoster oticus (MRI) (3)
Internal auditory canal (IAC) MRI image of a patient with herpes zoster oticus. The post-contrast 3D T1-weighted image shows contrast enhancement in the left vestibulocochlear nerve (small arrow) and the dura of the left IAC (l...
MRI enhancement of inner-ear structures and cranial nerves following varicella-zoster virus infection typically lasts less than 6 weeks but may apparently persist for at least 6 years in rare patients (52; 254). Such protracted resolution of MRI enhancement warrants consideration of other causes of labyrinthitis or intracanalicular acoustic neuroma (52; 254).
Some studies have found no clear prognostic indicators based on MRI images (138); others have suggested that enhancement limited to the geniculate ganglion and to the labyrinthine segment of the facial nerve indicates a good prognosis, whereas widespread enhancement of the facial nerve is often associated with a poor prognosis for facial nerve recovery (20).
Simultaneous postcontrast enhancement of the labyrinth and intratemporal cranial nerves can occur with viral or bacterial labyrinthitis, including herpes zoster oticus and Bell palsy (143; 138; 201; 220; 120; 218; 34). Abnormal contrast enhancement of inner ear soft-tissue structures may also occur with facial nerve or cochlear tumors, with posttraumatic facial paresis, following temporal bone surgery, and with rare arteriovenous anomalies of the area, although the intensity and distribution of enhancement can often differentiate such lesions (151; 201; 242). MRI findings in herpes zoster oticus can mimic intracanalicular acoustic neuroma (09; 92; 151b; 52; 81).
Management
|
• The treatment of herpes zoster oticus remains somewhat controversial, particularly in terms of the role of corticosteroids in combination with antivirals. | |
|
• Acyclovir facilitates healing of varicella-zoster virus infections, has a low rate of toxicity, and may help prevent postherpetic neuralgia. | |
|
• Early treatment with acyclovir (eg, 800 mg five times daily in adults) (and possibly steroids such as prednisone 60 mg daily for 3 to 5 days) may improve the prognosis of facial palsy and also possibly hearing loss associated with herpes zoster oticus but randomized, controlled trial data are lacking. | |
|
• An alternative to acyclovir is famciclovir (500 mg three times daily in adults), although the latter is more toxic. | |
|
• With severe peripheral facial paresis, a major consideration is ensuring protection of the ipsilateral eye, especially when the eyelids do not close fully volitionally or during sleep. | |
|
• Vestibular sedatives may help alleviate acute vertigo, especially during the first few days, when the eighth nerve is involved. |
The treatment of herpes zoster oticus remains somewhat controversial, particularly in terms of the role of corticosteroids in combination with antivirals (42; 48; 61; 62).
Antivirals. Acyclovir facilitates healing of varicella-zoster virus infections, has a low rate of toxicity, and may help prevent postherpetic neuralgia (71). In particular, immunocompromised patients with varicella-zoster virus infection should be promptly treated with high-dose acyclovir (1500 mg/m2 per day for children and 30 mg/kg per day for adults in three divided doses) (71). Acyclovir is also indicated in rare patients who develop associated central nervous system findings (104).
Early treatment with acyclovir (eg, 800 mg five times daily in adults) (and possibly steroids such as prednisone 60 mg daily for 3 to 5 days) may improve the prognosis of facial palsy and also possibly hearing loss associated with herpes zoster oticus, but adequate randomized, controlled trial data are lacking (50; 115; 226; 02; 171; 65; 135; 134; 219; 83; 225; 229; 166; 61).
Treatment is typically given for 1 to 2 weeks. Longer treatment does not apparently improve the outcome (244).
An alternative to acyclovir is famciclovir (500 mg three times daily in adults), although the latter is more toxic. In a retrospective study, recovery rates were higher following treatment with famciclovir plus steroids than with acyclovir plus steroids, especially in patients without hypertension and diabetes mellitus (130).
Corticosteroids. The addition of steroids is controversial, and randomized trials have suggested that corticosteroid therapy does not apparently improve the outcome (244), although restrospective observational data suggest a benefit of high-dose corticosteroid therapy in conjunction with antiviral therapy (62). Unfortunately, there have been few randomized controlled trials to assess the utility of corticosteroids as an adjuvant to antiviral therapy in herpes zoster oticus (230).
In a systematic review involving collectively 350 patients, the authors concluded that intratympanic corticosteroids have the potential to reduce nonrecovery in patients with Ramsay Hunt syndrome (61). However, the methods of intratympanic corticosteroid treatment varied among included studies. The timing of intratympanic corticosteroid treatment varied from daily for 10 days to once or twice a week. Patients treated with a combination of systemic corticosteroids and intratympanic corticosteroids were likely to achieve recovery of normal facial function. A subgroup analysis revealed that daily intratympanic corticosteroids reduced nonrecovery whereas non-daily intratympanic corticosteroids did not. Further well-designed randomized controlled trials are needed to confirm the effectiveness of intratympanic corticosteroids and establish an optimal treatment regimen.
Vertigo. Vestibular sedatives may help alleviate acute vertigo, especially during the first few days, when the eighth nerve is involved. Anecdotal reports are also available of vestibular rehabilitation training for peripheral vestibular dysfunction following herpes zoster oticus (76).
Eye protection. With severe peripheral facial paresis, a major consideration is ensuring protection of the ipsilateral eye, especially when the eyelids do not close fully volitionally or during sleep. Such patients have poor reflex eye closure and may have inadequate lacrimation and are, therefore, susceptible to corneal abrasions and infections. Ophthalmic lubricant should be placed in the affected eye (a viscous product is preferred especially at night). The eyelid can be held closed with tape or an inflexible convex eye shield can be placed over the eye for protection. A hydrophilic soft contact lens has also been used to bandage the cornea in such cases to prevent injury (248). It is potentially dangerous to use flexible eye patches or to attempt to keep the lid closed by applying a dressing held with pressure and tape over the eye; in such cases, the eye often opens under cover and is abraded by the patch or dressing.
Physical therapy. A metaanalysis of seven randomized controlled trials collectively involving 418 participants found that (1) physical therapy may reduce non-recovery in patients with peripheral facial palsy; (2) physical therapy may improve the composite score of the Sunnybrook facial grading system; and (3) the efficacy of physical therapy in reducing sequelae remained uncertain (177). However, the certainty of evidence was low or very low because the included studies had a high risk of bias, imprecision, or inconsistency; therefore, further well-designed randomized controlled trials are needed to confirm the efficacy of physical therapy.
Special considerations
Pregnancy
Varicella infection in women during pregnancy can result in maternal varicella pneumonia, intrauterine death, or severe congenital disease (congenital or fetal varicella syndrome). Congenital varicella syndrome is characterized by limb hypoplasia, skin abnormalities in dermatomal distribution, ocular abnormalities, encephalitis, microcephaly, cerebral malformations, epilepsy, mental retardation, and low birth weight.
Congenital varicella syndrome occurs in approximately 0.4% to 2% of infants born to women infected with varicella-zoster virus during the first two trimesters of pregnancy (56; 192; 94). Subclinical maternal infection can be cause congenital varicella syndrome (174).
Media
References
- 01
- Abramovich S, Prasher DK. Electrocochleography and brain-stem potentials in Ramsay Hunt syndrome. Arch Otolaryngol Head Neck Surg 1986;112(9):925-8. PMID 3741657
- 02
- Adour KK. Otological complications of herpes zoster. Ann Neurol 1994;35(Suppl):S62-4. PMID 8185302
- 03
- Ahmed EY, Rawahi HA, Amrani FA, Masaoudi LA, Yazidi LA. Ramsay Hunt syndrome associated with varicella-zoster virus encephalitis in a child. Sultan Qaboos Univ Med J 2024;24(1):127-30. PMID 38434459
- 04
- Aizawa H, Ohtani F, Furuta Y, Sawa H, Fukuda S. Variable patterns of varicella-zoster virus reactivation in Ramsay Hunt syndrome. J Med Virol 2004;74:355-60. PMID 15332286
- 05
- Al-Ani RM. Ramsay Hunt syndrome with cranial polyneuropathy and delayed facial nerve palsy: a case report. Cureus 2022;14(7):e27434. PMID 36051720
- 06
- Alicandri-Ciufelli M, Aggazzotti-Cavazza E, Genovese E, Monzani D, Presutti L. Herpes zoster oticus: a clinical model for a transynaptic, reflex pathways, viral transmission hypotheses. Neurosci Res 2012;74(1):7-9. PMID 22709534
- 07
- Alliegro MB, Dorrucci M, Pezzotti P, et al. Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV Seroconversion Study. Clin Infect Dis 1996;23(5):990-5. PMID 8922791
- 08
- Ananthapadmanabhan S, Soodin D, Sritharan N, Sivapathasingam V. Ramsay Hunt syndrome with multiple cranial neuropathy: a literature review. Eur Arch Otorhinolaryngol 2022;279(5):2239-44. PMID 34687339
- 09
- Anderson RE, Laskoff JM. Ramsay Hunt syndrome mimicking intracanalicular acoustic neuroma on contrast-enhanced MR. AJNR Am J Neuroradiol 1990;11(2):409. PMID 2107729
- 10
- Anonymous. Recommendations for the use of live attenuated varicella vaccine. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1995;95(5):791-6. PMID 7724330
- 11
- Anonymous. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996;45(RR-11):1-36. PMID 8668119
- 12
- Anonymous. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(RR-6):1-5. PMID 10366137
- 13
- Anonymous. American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000;105(1 Pt 1):136-41. PMID 10617719
- 14
- Anonymous. Shingrix--an adjuvanted, recombinant herpes zoster vaccine. Med Lett Drugs Ther 2017;59(1535):195-6. PMID 29186082
- 15
- Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352(22):2266-7. PMID 15930416
- 16
- Asnis DS, Micic L, Giaccio D. Ramsay Hunt syndrome presenting as a cranial polyneuropathy. Cutis 1996;57(6):421-4. PMID 8804844
- 17
- Aviel A, Marshak G. Ramsay Hunt syndrome: a cranial polyneuropathy. Am J Otolaryngol 1982;3:61-6. PMID 6981355
- 18
- Aydogdu I, Ataç E, Saltürk Z, et al. Pediatric Ramsay Hunt syndrome: analysis of three cases. Case Rep Otolaryngol 2015;2015:971249. PMID 26435868
- 19
- Barrow KO, Richards JS. Ramsay Hunt syndrome complicated by contralateral cerebral infarction. West Indian Med J 1996;45:127-8. PMID 9033235
- 20
- Berrettini S, Bianchi MC, Segnini G, Sellari-Franceschini S, Bruschini P, Montanaro D. Herpes zoster oticus: correlations between clinical and MRI findings. Eur Neurol 1998;39(1):26-31. PMID 9476720
- 21
- Bharadwaj S, Moffat AC, Wood B, Bharadwaj A. Herpetic cranial polyneuritis mimicking brain stem infarction-an atypical presentation of Ramsay Hunt syndrome. BMJ Case Rep 2016;2016. PMID 27251418
- 22
- Bharucha T, Ming D, Breuer J. A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother 2017;13(8):1789-97. PMID 28426274
- 23
- Bhattacharyya PC, Kakati S. Ramsay Hunt syndrome with aseptic meningitis. J Assoc Physicians India 1993;41:113-4. PMID 8335601
- 24
- Bjerkhoel A, Hyden D. Ramsay-Hunt syndrome in a preschool infant. ORL J Otorhinolaryngol Relat Spec 1989;51(4):251-4. PMID 2664634
- 25
- Blackley D, Friedman I, Wright I. Herpes zoster auris associated with facial nerve palsy and auditory nerve symptoms: a case report with histopathological findings. Acta Otolaryngol 1967;63:533-50. PMID 6037903
- 26
- Brandle P, Satoretti-Schefer S, Bohmer A, Wichman W, Fisch U. Correlation of MRI, clinical, and electroneuronographic findings in acute facial nerve palsy. Am J Otol 1996;17:154-61. PMID 8694122
- 27
- Brody IA, Wilkins RH. Ramsay Hunt syndrome. Arch Neurol 1968;18:583-9. PMID 4869674
- 28
- Byl FM, Adour KK. Auditory symptoms associated with herpes zoster or idiopathic facial paralysis. Laryngoscope 1977;87:372-9. PMID 557156
- 29
- Byun H, Cho YS, Jang JY, et al. Value of electroneurography as a prognostic indicator for recovery in acute severe inflammatory facial paralysis: a prospective study of Bell's palsy and Ramsay Hunt syndrome. Laryngoscope 2013;123(10):2526-32. PMID 23918352
- 30
- Cai Z, Li H, Wang X, et al. Prognostic factors of Bell's palsy and Ramsay Hunt syndrome. Medicine (Baltimore) 2017;96(2):e5898. PMID 28079835
- 31
- Carroll WM, Mastaglia FL. Optic neuropathy and ophthalmoplegia in herpes zoster oticus. Neurology 1979;29:726-9. PMID 312472
- 32
- Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011;60(44):1528. PMID 22071592
- 33
- Chapman SJ. Varicella in pregnancy. Semin Perinatol 1998;22:339-46. PMID 9738999
- 34
- Choi JW, Nahm H, Shin JE, Kim CH. Atypical clinical manifestations of herpes zoster oticus: diagnostic usefulness of magnetic resonance imaging. J Neurovirol 2019;25(6):874-82. PMID 31278535
- 35
- Chou CC, Lo YT, Su HC, Chang CM. Fear of falling as a potential complication of Ramsay Hunt syndrome in older adults: a case report. BMC Geriatr 2022;22(1):901. PMID 36434527
- 36
- Chung MS, Lee JH, Kim DY, et al. The clinical significance of findings obtained on 3D-FLAIR MR imaging in patients with Ramsay-Hunt syndrome. Laryngoscope 2015;125(4):950-5. PMID 25346250
- 37
- Citron D, Adour KK. Acoustic reflex and loudness discomfort in acute facial paralysis. Arch Otolaryngol 1978;104:303-6. PMID 655951
- 38
- Clarke P, Beer T, Cohrs R, Gilden DH. Configuration of latent varicella-zoster virus DNA. J Virol 1995;69:8151-4. PMID 7494340
- 39
- Cohen JI. A new vaccine to prevent herpes zoster. N Engl J Med 2015;372(22):2149-50. PMID 25916342
- 40
- Corral C, Quereda C, Muriel A, Martínez-Ulloa PL, González-Gómez FJ, Corral Í. Clinical spectrum and prognosis of neurological complications of reactivated varicella-zoster infection: the role of immunosuppression. J Neurovirol 2020;26(5):696-703. PMID 32696182
- 41
- Corti M, Villafañe MF, Correa J. Ramsay-Hunt syndrome: report of two cases with identification of the varicella zoster virus genome in cerebrospinal fluid. Biomedica 2021;41(4):625-30. PMID 34936248
- 42
- Coulson S, Croxson GR, Adams R, Oey V. Prognostic factors in herpes zoster oticus (Ramsay Hunt syndrome). Otol Neurotol 2011;32(6):1025-30. PMID 21725270
- 43
- Cunniffe HA, Cunniffe NG. Herpes zoster oticus with meningitis masquerading as malignant otitis externa. BMJ Case Rep 2019;12(6). PMID 31177200
- 44
- Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther 2016;16(2):265-71. PMID 26865048
- 45
- Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375(11):1019-32. PMID 27626517
- 46
- De S, Pfleiderer AG. An extreme and unusual variant of Ramsay Hunt syndrome. J Laryngol Otol 1999;113:670-1. PMID 10605568
- 47
- Denny-Brown D, Adams RD. Pathologic features of herpes zoster: a note on geniculate herpes. Arch Neurol Psychiatry 1944;51:216-31.
- 48
- de Ru JA, van Benthem PP. Combination therapy is preferable for patients with Ramsay Hunt syndrome. Otol Neurotol 2011;32(5):852-5. PMID 21593701
- 49
- DeVriese PP, Moesker WH. The natural history of facial paralysis in herpes zoster. Clin Otolaryngol 1988;13:289-98. PMID 2846216
- 50
- Dickins JR, Smith JT, Graham SS. Herpes zoster oticus: treatment with intravenous acyclovir. Laryngoscope 1988;98:776-9. PMID 3386386
- 51
- Djupesland G, Degre M, Stien R, Skrede S. Acute peripheral facial palsy. Part of a cranial polyneuropathy. Arch Otolaryngol 1977;103:641-4. PMID 200210
- 52
- Downie AC, Howlett DC, Koefman RJ, Banerjee AK, Tonge KA. Case report: prolonged contrast enhancement of the inner ear on magnetic resonance imaging in Ramsay Hunt syndrome. Br J Radiol 1994;67:819-21. PMID 8087491
- 53
- Easton HG. Zoster sine herpete causing acute trigeminal neuralgia. Lancet 1970;2:1065-6. PMID 4098355
- 54
- Edhonu-Elyetu Y. Significance of herpes zoster in HIV/AIDS in Kweneng district, Botswana. East Afr Med J 1998;75(7):379-81. PMID 9803626
- 55
- Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19(23-24):3076-90. PMID 11312002
- 56
- Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994;343(8912):1548-51. PMID 7802767
- 57
- Eskiizmir G, Uz U, Taskiran E, Unlű H. Herpes zoster oticus associated with varicella zoster virus encephalitis. Laryngoscope 2009;119(4):628-30. PMID 19213041
- 58
- Fang CW, Lin CC. Ramsay Hunt syndrome with hemiparesis and hemihypoesthesia: report of 2 cases. Acta Neurol Taiwan 2009;18(4):276-80. PMID 20329597
- 59
- Forbes HJ, Bhaskaran K, Grint D, et al. Incidence of acute complications of herpes zoster among immunocompetent adults in England: a matched cohort study using routine health data. Br J Dermatol 2021;184(6):1077-84. PMID 33216946
- 60
- Fueyo MA, Lookingbill DP. Herpes zoster and occult malignancy. J Am Acad Dermatol 1984;11:480-2. PMID 6480952
- 61
- Fujiwara T, Iwata S, Hosokawa Y, Mitani S. Intratympanic corticosteroid for Bell's palsy and Ramsay Hunt syndrome: systematic review and meta-analysis. Auris Nasus Larynx 2022;49(4):599-605. PMID 34980517
- 62
- Furukawa T, Abe Y, Ito T, et al. Benefits of high-dose corticosteroid and antiviral agent combination therapy in the treatment of House-Brackmann grade VI Ramsay Hunt syndrome. Otol Neurotol 2022;43(7):e773-9. PMID 35878642
- 63
- Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K. Detection of varicella-zoster virus DNA in patients with acute facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol 1997b;52:316-9. PMID 9210042
- 64
- Furuta Y, Ohtani F, Aizawa H, Fukuda S, Kawabata H, Bergstrom T. Varicella-zoster virus reactivation is an important cause of acute peripheral facial paralysis in children. Pediatr Infect Dis J 2005;24:97-101. PMID 15702035
- 65
- Furuta Y, Ohtani F, Mesuda Y, Fukuda S, Inuyama Y. Early diagnosis of zoster sine herpete and antiviral therapy for the treatment of facial palsy. Neurology 2000c;55:708-10. PMID 10980741
- 66
- Furuta Y, Ohtani F, Sawa H, Fukuda S, Inuyama Y. Quantitation of varicella-zoster virus DNA in patients with Ramsay Hunt syndrome and zoster sine herpete. J Clin Microbiol 2001;39:2856-9. PMID 11474003
- 67
- Furuta Y, Takasu T, Fukuda S, et al. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis 1992;166:1157-9. PMID 1328403
- 68
- Furuta Y, Takasu T, Suzuki S, Fukuda S, Inuyama Y, Nagashima K. Detection of latent varicella-zoster virus infection in human vestibular and spiral ganglia. J Med Virol 1997a;51:214-6. PMID 9139086
- 69
- Garg RK, Agrawal A, Nag D, Jha S. Herpes zoster oticus associated with facial, auditory and trigeminal involvement. J Assoc Physicians India 1992;40(1):45-6. PMID 1634465
- 70
- Gaudin RA, Remenschneider AK, Phillips K, et al. Facial palsy after dental procedures - Is viral reactivation responsible? J Craniomaxillofac Surg 2017;45(1):71-5. PMID 27939042
- 71
- Gerson AA. Zoster in immunosuppressed patients. In: Watson CP, editor. Herpes zoster and postherpetic neuralgia. Amsterdam: Elsevier Science Pub, 1993:73-86.
- 72
- Gilden DH. Varicella-zoster virus vaccine–grown-ups need it, too. N Engl J Med 2005;352(22):2344-6. PMID 15930426
- 73
- Gilden DH, Bennett JL, Kleinschmidt-DeMasters BK, Song DD, Yee AS, Steiner I. The value of cerebrospinal fluid antiviral antibody in the diagnosis of neurologic disease produced by varicella zoster virus. J Neurol Sci 1998;159:140-14. PMID 9741397
- 74
- Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342:635-45. PMID 10699164
- 75
- Gilden DH, Wright RR, Schneck SA, Gwaltney JM Jr, Mahalingam R. Zoster sine herpete, a clinical variant. Ann Neurol 1994;35:530-3. PMID 8179298
- 76
- Gill-Body KM, Krebs DE, Parker SW, Riley PO. Physical therapy management of peripheral vestibular dysfunction: two clinical case reports. Phys Ther 1994;74:129-42. PMID 8290618
- 77
- Gillette BT, Heilbronn CM. A rare case of vocal cord paralysis in the setting of Ramsay Hunt syndrome. Cureus 2023;15(3):e36027. PMID 37051001
- 78
- Glesby MJ, Moore RD, Chaisson RE. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis 1993;168(5):1264-8. PMID 8228361
- 79
- Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347(5):340-6. PMID 12151472
- 80
- Goldman GS. Universal varicella vaccination: efficacy trends and effect on herpes zoster. Int J Toxicol 2005;24(4):205-13. PMID 16126614
- 81
- Goldsmith P, Zammit-Maempel I, Meikle D. Ramsay Hunt syndrome mimicking acoustic neuroma on MRI. J Laryngol Otol 1995;109:1013-5. PMID 7499937
- 82
- Grahn A, Bergström T, Runesson J, Studahl M. Varicella-zoster virus (VZV) DNA in serum of patients with VZV central nervous system infections. J Infect 2016;73(3):254-60. PMID 27317379
- 83
- Grose C, Bonthius D, Afifi AK. Chickenpox and the geniculate ganglion: facial nerve palsy, Ramsay Hunt syndrome and acyclovir treatment. Pediatr Infect Dis J 2002;21:615-7. PMID 12237590
- 84
- Grote V, von Kries R, Rosenfeld E, Belohradsky BH, Liese J. Immunocompetent children account for the majority of complications in childhood herpes zoster. J Infect Dis 2007;196(10):1455-8. PMID 18008223
- 85
- Gruber MF. BLA [Biologics License Application] approval for zoster vaccine recombinant, adjuvanted. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581750.pdf. Accessed December 19, 2017.
- 86
- Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985;76:512-7. PMID 3863086
- 87
- Guldberg-Moller J, Olsen S, Kettel K. Histopathology of the facial nerve in herpes zoster oticus. Arch Otolaryngol 1959;69:266-75. PMID 13626314
- 88
- Gunbey HP, Kutlar G, Aslan K, Sayit AT, Incesu L. Magnetic resonance imaging evidence of varicella zoster virus polyneuropathy: involvement of the glossopharyngeal and vagus nerves associated with Ramsay Hunt syndrome. J Craniofac Surg 2016;27(3):721-3. PMID 27092925
- 89
- Gundin G, Monedero G, Teba JM, Perez Esteban L, Sanz R. Varicella-zoster infection with isolated cochleovestibular affectation (without facial palsy). Acta Otorrinolaringol Esp 2006;57(4):189-92. PMID 16686230
- 90
- Haginomori S, Ichihara T, Mori A, Kanazawa A, Kawata R, Tang H, Mori Y. Varicella-zoster virus-specific cell-mediated immunity in Ramsay Hunt syndrome. Laryngoscope 2016;126(1):E35-9. PMID 26183571
- 91
- Hah YM, Kim SH, Jung J, et al. Prognostic value of the blink reflex test in Bell's palsy and Ramsay-Hunt syndrome. Auris Nasus Larynx 2018;45(5):966-70. PMID 29402606
- 92
- Han MH, Jabour BA, Andrews JC, et al. Nonneoplastic enhancing lesions mimicking intracanalicular acoustic neuroma on gadolinium-enhanced MR images. Radiology 1991;179:795-6. PMID 2027994
- 93
- Han Y, Lui L, Zhang J, Du X, Fan W. Clinical Analysis of 3D-fluid attenuated inversion recovery and T1volume interpolated body examination sequences on delayed gadolinium-enhanced scanning in Ramsay Hunt syndrome. J Int Adv Otol 2023;19(5):407-13. PMID 37789628
- 94
- Harger JH, Ernest JM, Thurnau GR, et al. Frequency of congenital varicella syndrome in a prospective cohort of 347 pregnant women. Obstet Gynecol 2002;100:260-5. PMID 12151147
- 95
- Hato N, Kisaki H, Honda N, Gyo K, Murakami S, Yanagihara N. Ramsay Hunt syndrome in children. Ann Neurol 2000;48:254-6. PMID 10939578
- 96
- Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900;23:353-523.
- 97
- Heathfield KW, Mee AS. Prognosis of the Ramsay Hunt syndrome. Br Med J 1978;1:343-4. PMID 623985
- 98
- Heuchan AM, Isaacs D. The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases. Med J Aust 2001;174(6):288-92. PMID 11297117
- 99
- Hiraide F, Kakoi H, Miyoshi S, Morita M. Acute profound deafness in Ramsay Hunt syndrome. Two case reports. Acta Otolaryngol Suppl 1988;456:49-54. PMID 2852431
- 100
- Hiroshige K, Ikeda M, Hondo R. Detection of varicella zoster virus DNA in tear fluid and saliva of patients with Ramsay Hunt syndrome. Otol Neurotol 2002;23:602-7. PMID 12170168
- 101
- Honda N, Yanagihara N, Hato N, Kisak H, Murakami S, Gyo K. Swelling of the intratemporal facial nerve in Ramsay Hunt syndrome. Acta Otolaryngol 2002;122:348-52. PMID 12030588
- 102
- Hong JP, Lee JY, Kim MB. Vestibular mapping in Ramsay-Hunt syndrome and idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2023;280(12):5251-8. PMID 37210462
- 103
- Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20. PMID 14267505
- 104
- Hu S, Walker M, Czartoski T, et al. Acyclovir responsive brain stem disease after Ramsay Hunt syndrome. J Neurol Sci 2004;217:111-3. PMID 14675618
- 105
- Hung CW, Wang SJ, Chen SP, Lirng JF, Fuh JL. Trigeminal herpes zoster and Ramsay Hunt syndrome with a lesion in the spinal trigeminal nucleus and tract. J Neurol 2010;257(6):1045-6. PMID 20155276
- 106
- Hunt JR. On herpetic inflammations of the geniculate ganglion: a new syndrome and its complications. J Nerve Ment Dis 1907a;34:73-96.
- 107
- Hunt JR. Otalgia considered as an affection of the sensory system of the seventh cranial nerve. Arch Otol 1907b;37:543-56.
- 108
- Hunt JR. A further contribution to the herpetic inflammations of the geniculate ganglion. Am J Med Sci 1908;136:226-41.
- 109
- Hunt JR. The sensory system of the facial nerve and its symptomatology. J Nerv Ment Dis 1909;36:321-50.
- 110
- Hunt JR. The symptom-complex of the acute posterior poliomyelitis of the geniculate, auditory, glossopharyngeal and pneumogastric ganglia. Arch Intern Med 1910;5:631-75.
- 111
- Hunt JR. The sensory field of the facial nerve: a further contribution to the symptomatology of the geniculate ganglion. Brain 1915;38:418-46.
- 112
- Hunt JR. Geniculate neuralgia (neuralgia of the nervus facialis): a further contribution to the sensory system of the facial nerve and its neuralgic conditions. Arch Neurol Psychiatry 1937;37:253-85.
- 113
- Hwang YS, Kim YS, Shin BS, Kang HG. Two cases of Ramsay-Hunt syndrome following varicella zoster viral meningitis in young immunocompetent men: case reports. BMC Neurol 2023;23(1):43. PMID 36707826
- 114
- Ikeda M, Hiroshige K, Abiko Y, Onoda K. Impaired specific cellular immunity to the varicella-zoster virus in patients with herpes zoster oticus. J Laryngol Otol 1996;110:918-21. PMID 8977852
- 115
- Inamura H, Aoyagi M, Tojima H, Koike Y. Effects of Aciclovir in Ramsay Hunt syndrome. Acta Otolaryngol Suppl 1988;446:111-3. PMID 3166577
- 116
- Iragui VJ. Auditory dysfunction in Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 1986;49:824-6. PMID 3746312
- 117
- Izumi AK, Kitagawa K. Ramsay Hunt syndrome: a case report with cranial nerve XII involvement. J Am Acad Dermatol 2007;57(6):1102-3. PMID 18021862
- 118
- Jan AM, McGuire TP, Clokie CM, Sandor GK. Unilateral facial swelling caused by Ramsay Hunt syndrome resembles odontogenic infection. J Can Dent Assoc 2006;72:829-32. PMID 17109804
- 119
- Jarrett WH. Horner's syndrome with geniculate zoster occurring in association with trigeminal herpes in which the ophthalmic division was spared. Am J Ophthalmol 1967;63:326-30. PMID 6018668
- 120
- Jonsson L, Tien R, Engstrom M, Thuomas KA. Gd-DPTA enhanced MRI in Bell's palsy and herpes zoster oticus: an overview and implications for future studies. Acta Otolaryngol 1995;115:577-84. PMID 8928627
- 121
- Kaberos A, Balatsouras DG, Korres SG, Kandiloros D, Economou C. Audiological assessment in Ramsay Hunt syndrome. Ann Otol Rhinol Laryngol 2002;111:68-76. PMID 11800372
- 122
- Kanerva M, Jones S, Pitkaranta A. Ramsay Hunt syndrome: long-term facial palsy outcome assessed face-to-face by three different grading scales and compared to patient self-assessment. Eur Arch Otorhinolaryngol 2021;278(6):1781-7. PMID 32748187
- 123
- Kansu L, Yilmaz I. Herpes zoster oticus (Ramsay Hunt syndrome) in children: case report and literature review. Int J Pediatr Otorhinolaryngol 2012;76(6):772-6. PMID 22445801
- 124
- Kaski D, Davies N, Seemungal BM. Varicella-zoster virus meningo-rhombencephalitis presenting as Ramsey Hunt. Neurology 2012;79(23):2291-2. PMID 23212190
- 125
- Keane JR. Delayed trochlear nerve palsy in a case of zoster oticus. Arch Ophthalmol 1975;93:382-3. PMID 1147811
- 126
- Kikuoka Y, Haginomori SI, Ayani Y, et al. Recurrent facial palsy: Characteristics of ipsilateral and alternative palsies of 104 cases. Auris Nasus Larynx 2023;50(4):507-12. PMID 36503866
- 127
- Kim CH, Choi JW, Han KJ, Lee YS, Shin JE. Direction-fixed and direction-changing positional nystagmus in Ramsay Hunt syndrome. Otol Neurotol 2018;39(3):e209-13. PMID 29342047
- 128
- Kim CH, Choi H, Shin JE. Characteristics of hearing loss in patients with herpes zoster oticus. Medicine (Baltimore) 2016;95(46):e5438. PMID 27861389
- 129
- Kim D, Bhimani M. Ramsay Hunt syndrome presenting as simple otitis externa. CJEM 2008;10(3):247-50. PMID 19019276
- 130
- Kim HJ, Jung J, Kim SS, Byun JY, Park MS, Yeo SG. Comparison of acyclovir and famciclovir for Ramsay Hunt syndrome. Otol Neurotol 2017;38(5):754-8. PMID 28221283
- 131
- Kim JH, Chung PW, Oh S, et al. Ramsay Hunt syndrome complicated by a brainstem lesion. J Clin Virol 2007;39(4):322-5. PMID 17604687
- 132
- Kim YH, Chang MY, Jung HH, et al. Prognosis of Ramsay Hunt syndrome presenting as cranial polyneuropathy. Laryngoscope 2010;120(11):2270-6. PMID 20824789
- 133
- Kimitsuki T, Komiyama S. Ramsay-Hunt syndrome in a 4-year-old child. Eur Arch Otorhinolaryngol 1999;256(Suppl 1):S6-7. PMID 10337517
- 134
- Kinishi M, Amatsu M, Mohri M, Saito M, Hasegawa T, Hasegawa S. Acyclovir improves recovery rate of facial nerve palsy in Ramsay Hunt syndrome. Auris Nasus Larynx 2001;28(3):223-6. PMID 11489365
- 135
- Ko JY, Sheen TS, Hsu MM. Herpes zoster oticus treated with acyclovir and prednisolone: clinical manifestations and analysis of prognostic factors. Clin Otolaryngol 2000;25:139-42. PMID 10816219
- 136
- Koga C, Iwamoto O, Aoki M, Nakamura C, Kusukawa J, Matsuishi T. Ramsay-Hunt syndrome with vesicular stomatitis in a 4-year-old infant. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(6):e37-9. PMID 17138164
- 137
- Kohler A, Chofflon M, Sztajzel R, Magistris MR. Cerebrospinal fluid in acute peripheral facial palsy. J Neurol 1999;246:165-9. PMID 10323312
- 138
- Korzec K, Sobol SM, Kubal W, Mester SJ, Winzelberg G, May M. Gadolinium-enhanced magnetic resonance imaging of the facial nerve in herpes zoster oticus and Bell's palsy: clinical implications. Am J Otol 1991;12:163-8. PMID 1882962
- 139
- Kuhweide R, Van de Steene V, Vlaminck S, Casselman JW. Ramsay Hunt syndrome: pathophysiology of cochleovestibular symptoms. J Laryngol Otol 2002;116:844-8. PMID 12437843
- 140
- Kuo MJ, Drago PC, Proops DW, Chavda SV. Early diagnosis and treatment of Ramsay Hunt syndrome: the role of magnetic resonance imaging. J Laryngol Otol 1995;109:777-80. PMID 7561508
- 141
- Kusakari J, Takeyama M, Kawase T, Takahashi K, Sasaki Y, Takasaka T. Studies with electrocochleography and auditory brainstem response in Ramsay Hunt syndrome. Acta Otolaryngol Suppl 1988;446:81-4. PMID 3166594
- 142
- Kuya J, Kuya K, Shinohara Y, et al. Usefulness of high-resolution 3d multi-sequences for peripheral facial palsy: differentiation between Bell's palsy and Ramsay Hunt syndrome. Otol Neurotol 2017;38(10):1523-7. PMID 29135869
- 143
- LaBagnara J Jr, Jahn AF, Habif DV Jr, Solomon EM. MRI findings in two cases of acute facial paralysis. Otolaryngol Head Neck Surg 1989;101:562-5. PMID 2512536
- 144
- Lackner A, Kessler HH, Walch C, Quasthoff S, Raggam RB. Early and reliable detection of herpes simplex virus type 1 and varicella zoster virus DNAs in oral fluid of patients with idiopathic peripheral facial nerve palsy: Decision support regarding antiviral treatment. J Med Virol 2010;82(9):1582-5. PMID 20648613
- 145
- Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372(22):2087-96. PMID 25916341
- 146
- Lanska DJ. Disorders of the special senses in the elderly. In: Nair A, Sabbagh M, editors. Geriatric neurology. Chichester, West Sussex, UK: John Wiley & Sons, 2014:396-459.
- 147
- Lanska DJ, Hunt JR. In: Aminoff MJ, Daroff RB, editors. Encyclopedia of the neurological sciences. 2nd edition. Oxford: Academic Press/Elsevier, 2014;2:634-5.
- 148
- Lee J, Choi JW, Kim CH. Features of audio-vestibular deficit and 3D-FLAIR temporal bone MRI in patients with herpes zoster oticus. Viruses 2022;14(11):2568. PMID 36423176
- 149
- Lee J, Choi B, Noh H, Jeong H, Shin JE, Kim CH. Nystagmus in Ramsay Hunt syndrome with or without dizziness. Neurol Sci 2021;42(1):193-8. PMID 32592105
- 150
- Lewis GW. Zoster sine herpete. Br Med J 1958;34:418-21. PMID 13560886
- 151
- Li J, Tio FO, Jinkins JR. Contrast-enhanced MRI of healed pathologic vertebral compression fracture mimicking active disease in a patient treated for lymphoma. Neuroradiology 1993a;35:269. PMID 8232875
- 152
- Li J, Xiong L, Jinkins JR. Gadolinium-enhanced MRI in a patient with AIDS and the Ramsay-Hunt syndrome. Neuroradiology 1993b;35:269. PMID 8492890
- 153
- Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 2000;181:1897-905. PMID 10837168
- 154
- Liu Q, Zhou X, Li Z. Acute myelitis with multicranial neuritis caused by Varicella zoster virus: a case report. BMC Neurol 2022;22(1):45. PMID 35123429
- 155
- Locksley RM, Flourney N, Sullivan KM, Meyers J. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985;152:1172-81. PMID 3905982
- 156
- Louis ED. James Ramsay Hunt (1874-1937). J Neurol 2004;251:240-1. PMID 14991365
- 157
- Louis ED, Williams M. A biography of James Ramsay Hunt (1874-1937). J Hist Neurosci 2003;12:266-75. PMID 14628542
- 158
- Lu YC, Young YH. Vertigo from herpes zoster oticus: superior or inferior vestibular nerve origin. Laryngoscope 2003;113:307-11. PMID 12567087
- 159
- Mansour AM, Bailey BJ. Ocular findings in Ramsay Hunt syndrome. J Neuroophthalmol 1997;17:199-201. PMID 9304535
- 160
- Martin-Sanz E, Rueda A, Esteban-Sanchez J, Yanes J, Rey-Martinez J, Sanz-Fernandez R. Vestibular restoration and adaptation in vestibular neuritis and Ramsay Hunt syndrome with vertigo. Otol Neurotol 2017;38(7):e203-8. PMID 28570417
- 161
- Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998;27:1510-3. PMID 9868668
- 162
- May M, Fria TJ, Blumenthal F, Curtin H. Facial paralysis in children: differential diagnosis. Otolaryngol Head Neck Surg 1981;89:841-8. PMID 6799919
- 163
- Mayo DR, Booss J. Varicella zoster-associated neurologic disease without skin lesions. Arch Neurol 1989;46:313-5. PMID 2537615
- 164
- McCandless GA, Schumacher MH. Auditory dysfunction with facial paralysis. Arch Otolaryngol 1979;105:271-4. PMID 435151
- 165
- McNulty A, Li Y, Radtke U, et al. Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin Med 1997;73:467-70. PMID 9582462
- 166
- Monsanto RD, Bittencourt AG, Bobato Neto NJ, Beilke SC, Lorenzetti FT, Salomone R. Treatment and prognosis of facial palsy on Ramsay Hunt syndrome: results based on a review of the literature. Int Arch Otorhinolaryngol 2016;20(4):394-400. PMID 27746846
- 167
- Morgan D, Mahe C, Malamba S, Okongo M, Mayanja B, Whitworth J. Herpes zoster and HIV-1 infection in a rural Ugandan cohort. AIDS 2001;15(2):223-9. PMID 11216931
- 168
- Morgan-Capner P, Crowcroft NS; PHLS Joint Working Party of the Advisory Committees of Virology and Vaccines and Immunisation. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun Dis Public Health 2002;5(1):59-71. PMID 12070980
- 169
- Morishima N, Yagi R, Shimizu K, Ota S. Prognostic factors of synkinesis after Bell's palsy and Ramsay Hunt syndrome. Auris Nasus Larynx 2013;40(5):431-4. PMID 23419994
- 170
- Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015;60(6):900-9. PMID 25416754
- 171
- Murakami S, Hato N, Horiuchi J, Honda N, Gyo K, Yanagihara N. Treatment of Ramsay Hunt syndrome with acyclovir-prednisone: significance of early diagnosis and treatment. Ann Neurol 1997;41:353-7. PMID 9066356
- 172
- Murakami S, Honda N, Mizobuchi M, Nakashiro Y, Hato N, Gyo K. Rapid diagnosis of varicella zoster virus infection in acute facial palsy. Neurology 1998a;51:1202-5. PMID 9781562
- 173
- Murakami S, Nakashiro Y, Mizobuchi M, Hato N, Honda N, Gyo K. Varicella-zoster virus distribution in Ramsay Hunt syndrome revealed by polymerase chain reaction. Acta Otolaryngol 1998b;118:145-9. PMID 9583779
- 174
- Mustonen K, Mustakangas P, Valanne L, Professor MH, Koskiniemi M. Congenital varicella-zoster virus infection after maternal subclinical infection: clinical and neuropathological findings. J Perinatol 2001;21(2):141-6. PMID 11324362
- 175
- Naburi AE, Leppard B. Herpes zoster and HIV infection in Tanzania. Int J STD AIDS 2000;11:254-6. PMID 10772090
- 176
- Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990;49(8):630-3. PMID 2168693
- 177
- Nakano H, Fujiwara T, Tsujimoto Y, et al. Physical therapy for peripheral facial palsy: A systematic review and meta-analysis. Auris Nasus Larynx 2024;51(1):154-60. PMID 37149416
- 178
- Nakata S, Mizuno T, Naganawa S, et al. 3D-FLAIR MRI in facial nerve paralysis with and without audio-vestibular disorder. Acta Otolaryngol 2010;130(5):632-6. PMID 19916898
- 179
- Neuzil KM, Griffin MR. Preventing shingles and its complications in older persons. N Engl J Med 2016;375(11):1079-80. PMID 27626522
- 180
- Nogueira RG, Seeley WW. Ramsay Hunt syndrome associated with spinal trigeminal nucleus and tract involvement on MRI. Neurology 2003;61:1306-7. PMID 14610151
- 181
- O’Driscoll KJ, McShane DP. Herpes zoster oticus--diagnosis and treatment. Ir Med J 1992;85(3):115-6. PMID 1399478
- 182
- Ogilvie MM. Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect 1998;36(Suppl 1):31-8. PMID 9514106
- 183
- Ogita S, Terada K, Niizuma T, Kosaka Y, Kataoka N. Characteristics of facial nerve palsy during childhood in Japan: frequency of varicella-zoster virus association. Pediatr Int 2006;48:245-9. PMID 16732788
- 184
- Oh D, Park SH. Teaching NeuroImages: MRI in Ramsay-Hunt syndrome after trigeminal zoster. Neurology 2010;74(9):e33. PMID 20194908
- 185
- Ohtani F, Furuta Y, Aizawa H, Fukuda S. Varicella-zoster virus load and cochleovestibular symptoms in Ramsay Hunt syndrome. Ann Otol Rhinol Laryngol 2006;115(3):233-8. PMID 16572614
- 186
- Ortiz GA, Koch S, Forteza A, Romano J. Ramsay hunt syndrome followed by multifocal vasculopathy and posterior circulation strokes. Neurology 2008;70(13):1049-51. PMID 18362285
- 187
- Osaki Y, Matsubayashi K, Okumiya K, Wada T, Doi Y. Polyneuritis cranialis due to varicella-zoster virus in the absence of rash. Neurology 1995;45:2293. PMID 8848213
- 188
- Osumi A, Tien RD. MR findings in a patient with Ramsay-Hunt syndrome. J Comput Assist Tomogr 1990;14(6):991-3. PMID 2229582
- 189
- Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45(12 Suppl 8):S41-6. PMID 8545018
- 190
- Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84. PMID 15930418
- 191
- Ozel L, Toros SZ, Unal E, et al. Ramsay Hunt syndrome with atypical progress in a renal transplant recipient: a case report. Exp Clin Transplant 2011;9(6):413-6. PMID 22142050
- 192
- Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994;330:901-5. PMID 8114861
- 193
- Pavlidis P, Cámara RJA, Kekes G, Gouveris H. Bilateral taste disorders in patients with Ramsay Hunt syndrome and Bell palsy. Ann Neurol 2018;83(4):807-15. PMID 29537615
- 194
- Petersen PT, Bodilsen J, Jepsen MPG, et al. Ramsay Hunt syndrome and concurrent varicella-zoster virus meningitis in Denmark: A nationwide cohort study. J Med Virol 2023;95(12):e29291. PMID 38058258
- 195
- Proctor L, Perlman H, Lindsay J, Matz G. Acute vestibular paralysis in herpes zoster oticus. Ann Otol Rhinol Laryngol 1979;88:303-10. PMID 313735
- 196
- Pupic-Bakrac J, Pupić-Bakrač A, Terkeš V, Baraka I. Cranial polyneuropathy caused by herpes zoster infection: a retrospective single-center analysis. Eur Arch Otorhinolaryngol 2021;278(2):517-23. PMID 32776261
- 197
- Ragozzino MW, Melton LJ, Kurland LT. Population-based study of herpes zoster and its sequelae. Medicine 1982a;61:310-6. PMID 6981045
- 198
- Ragozzino MW, Melton LJ, Kurland LT. Risk of cancer after herpes zoster – a population-based study. N Engl J Med 1982b;307:383-97. PMID 6979711
- 199
- Ricigliano VAG, Saraceno L, Cavalli M, Rodegher M, Meola G. Slowly progressing varicella zoster brainstem encephalitis complicating Ramsay Hunt syndrome in an immunocompetent patient: case report and review of the literature. J Neurovirol 2017;23(6):922-8. PMID 28905216
- 200
- Robillard RB, Hilsinger RL Jr, Adour KK. Ramsay Hunt facial paralysis: clinical analyses of 185 patients. Otolaryngol Head Neck Surg 1986;95:292-7. PMID 3108776
- 201
- Rovira Canellas A, Sanchez Torres C, Grivé Isern E, et al. Ramsay-Hunt syndrome and high-resolution 3DFT MRI. J Comput Assist Tomogr 1993;17:495-7. PMID 8491921
- 202
- Rusthoven JJ, Ahlgren P, Elhakim T, et al. Varicella-zoster infection in adult cancer patients: a population study. Arch Intern Med 1988;148:1561-6. PMID 3382302
- 203
- Sakoh T, Kanzaki M, Miyamoto A, et al. Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. BMC Cancer 2019;19(1):1220. PMID 31842803
- 204
- Sartoretti-Schefer S, Kollias S, Valavanis A. Ramsay Hunt syndrome associated with brain stem enhancement. AJNR Am J Neuroradiol 1999;20:278-80. PMID 10094353
- 205
- Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54(7):922-8. PMID 22291101
- 206
- Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989;74:1424-7. PMID 2548641
- 207
- Schulz P, Arbusow V, Strupp M, Dieterich M, Sautier W, Brandt T. Sympathetic contralateral vestibulopathy after unilateral zoster oticus. J Neurol Neurosurg Psychiatry 1999;66:672-6. PMID 10209186
- 208
- Scott MJ Sr, Scott MJ Jr. Ipsilateral deafness and herpes zoster ophthalmicus. Arch Dermatol 1983;119:235-6. PMID 6600599
- 209
- Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002;287(5):606-11. PMID 11829699
- 210
- Shapiro BE, Slattery M, Pessin MS. Absence of auricular lesions in Ramsay Hunt syndrome. Neurology 1994;44:773-4. PMID 8164846
- 211
- Sheik-Ali S, Jiang Y, Nasef H, Sproson E, Tuohy O. Bilateral sequential Ramsay Hunt syndrome in an immunocompromised adult: a rare entity. Ann R Coll Surg Engl 2024;106(2):197-9. PMID 36448928
- 212
- Shen YY, Dai TM, Liu HL, Wu W, Tu JL. Ramsay Hunt syndrome complicated by brainstem encephalitis in varicella-zoster virus infection. Chin Med J (Engl) 2015;128(23):3258-9. PMID 26612307
- 213
- Shim HJ, Jung H, Park DC, Lee JH, Yeo SG. Ramsay Hunt syndrome with multicranial nerve involvement. Acta Otolaryngol 2011;131(2):210-5. PMID 21070092
- 214
- Shin DH, Kim BR, Shin JE, Kim CH. Clinical manifestations in patients with herpes zoster oticus. Eur Arch Otorhinolaryngol 2016;273(7):1739-43. PMID 26308524
- 215
- Steele L, Ghedia R, Ahmad H, Mace A. Ramsay Hunt syndrome with cranial polyneuropathy with features of supraglottitis. BMJ Case Rep 2017;2017. PMID 28784901
- 216
- Stornaiuolo A, Iodice R, De Simone R, et al. Multiple cranial neuropathy due to varicella zoster virus reactivation without vesicular rash: a challenging diagnosis. Neurol Sci 2023;44(10):3687-9. PMID 37156980
- 217
- Sun WL, Yan JL, Chen LL. Ramsay Hunt syndrome with unilateral polyneuropathy involving cranial nerves V, VII, VIII, and XII in a diabetic patient. Quintessence Int 2011;42(10):873-7. PMID 22026001
- 218
- Suzuki F, Furuta Y, Ohtani F, Fukuda S, Inuyama Y. Herpes virus reactivation and gadolinium-enhanced magnetic resonance imaging in patients with facial palsy. Otol Neurotol 2001;22:549-53. PMID 11449115
- 219
- Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 2001;71:149-54. PMID 11459884
- 220
- Tada Y, Aoyagi M, Tojima H, et al. Gd-DTPA enhanced MRI in Ramsay Hunt syndrome. Acta Otolaryngol Suppl 1994;511:170-4. PMID 8203224
- 221
- Tecellioglu M, Kamisli S, Erbay MF, Kamisli O, Ozcan C. A rare presentation of cranial polyneuropathy without rash caused by varicella zoster virus. Med Arch 2017;71(4):293-5. PMID 28974853
- 222
- Terada K, Niizuma T, Kawano S, Kataoka N, Akisada T, Orita Y. Detection of varicella-zoster virus DNA in peripheral mononuclear cells from patients with Ramsay Hunt syndrome or zoster sine herpete. J Med Virol 1998;56(4):359-63. PMID 9829642
- 223
- Thiel D, Derfuss T, Strupp M, Gilden DH, Arbusow V, Brandt T. Cranial nerve palsies: herpes simplex virus type 1 and varicella-zoster virus latency. Ann Neurol 2002;51(2):273-4. PMID 11835389
- 224
- Turner JE, Geunes PM, Schuman NJ. Cranial polyneuropathy--Ramsay Hunt’s syndrome: case report and discussion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:354-7. PMID 9084199
- 225
- Uri N, Greenberg E, Kitzes-Cohen R, Doweck I. Acyclovir in the treatment of Ramsay Hunt syndrome. Otolaryngol Head Neck Surg 2003;129:379-81. PMID 14574292
- 226
- Uri N, Greenberg E, Meyer W, Kitzes-Cohen R. Herpes zoster oticus: treatment with acyclovir. Ann Otol Rhinol Laryngol 1992;101:161-2. PMID 1739262
- 227
- U.S. Food and Drug Administration. FDA licenses new vaccine to reduce older Americans’ risk of shingles. 2006:P06-73. Available at: https://www.pharmaceuticalonline.com/doc/fda-licenses-new-vaccine-to-reduce-older-amer-0001. Accessed 2006.
- 228
- U.S. Food and Drug Administration. FDA news release: FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age. March 24, 2011. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6044a5.htm. Accessed 2017.
- 229
- Uscategui T, Doree C, Chamberlain IJ, Burton MJ. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008a;(4):CD006851. PMID 18843734
- 230
- Uscategui T, Doree C, Chamberlain IJ, Burton MJ. Corticosteroids as adjuvant to antiviral treatment in Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008b;(3):CD006852. PMID 18646170
- 231
- Vázquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005;352(5):439-40. PMID 15689581
- 232
- Ventura A. Varicella vaccination guidelines for adolescents and adults. Am Fam Physician 1997;55:1220-4. PMID 9092283
- 233
- Verhulst E, Van Lammeren M, Dralands L. Diplopia from skew deviation in Ramsey-Hunt syndrome. A case report. Bull Soc Belge Ophtalmol 2000;(278):27-32. PMID 11761557
- 234
- von Bokay J. Über den ätiologischen Zusammenhang der Varizellen mit gewissen Fällen von Herpes Zoster. Wein Klin Wochenschr 1909;22:323-6.
- 235
- Wackym PA. Molecular temporal bone pathology: II. Ramsay Hunt syndrome (herpes zoster oticus). Laryngoscope 1997;107:1165-75. PMID 9292598
- 236
- Wackym PA, Popper P, Kerner MM, Grody WW. Varicella-zoster DNA in temporal bones of patients with Ramsay Hunt syndrome. Lancet 1993;342:1555. PMID 7902926
- 237
- Wayman DM, Pham HN, Byl FM, Adour KK. Audiological manifestations of Ramsay Hunt syndrome. J Laryngol Otol 1990;104:104-8. PMID 2324614
- 238
- Weller TH, Stoddard MB. Intranuclear inclusion bodies in cultures of human tissue inoculated with varicella vesicle fluid. J Immunol 1952;68:311-9. PMID 14938547
- 239
- Weller TH, Witton HM, Bell EJ. The etiologic agents of varicella and herpes zoster. Serologic studies with the viruses as propagated in vitro. J Exp Med 1958;108:843-68. PMID 13598817
- 240
- Wigdahl B, Rong BL, Kinney-Thomas E. Varicella-zoster virus infection of human sensory neurons. Virology 1986;152:384-99. PMID 2425480
- 241
- Wilson A, Sharp M, Koropchak C, Ting S, Arvin A. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocytic immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-26. PMID 1309369
- 242
- Wilson DF, Talbot JM, Hodgson RS. Magnetic resonance imaging-enhancing lesions of the labyrinth and facial nerve. Clinical correlation. Arch Otolaryngol Head Neck Surg 1994;120:560-4. PMID 8172709
- 243
- Wise RP, Braun MM, Seward JF, et al. Pharmacoepidemiologic implications of erroneous varicella vaccinations in pregnancy through confusion with Varicella zoster immune globulin. Pharmacoepidemiol Drug Saf 2002;11(8):651-4. PMID 12512240
- 244
- Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900. PMID 8114860
- 245
- Xanthopoulos J, Noussios G, Papaioannides D, Exarchakos G, Assimakopoulos D. Ramsay Hunt syndrome presenting as a cranial polyneuropathy. Acta Otorhinolaryngol Belg 2002;56:319-23. PMID 12244896
- 246
- Yamakawa K, Hamada M, Takeda T. Different real-time PCR assays could lead to a different result of detection of varicella-zoster virus in facial palsy. J Virol Methods 2007;139:227-9. PMID 17134766
- 247
- Yacovino DA, Perez Akly MS, Ibañez T, Cherchi M. Vestibular nucleus involvement in patients with acute vertigo due to herpes zoster oticus or vestibular neuritis. Neurology 2023;101(14):e1461-5. PMID 37460229
- 248
- Yamane SJ. Soft contact lens bandage for Ramsay Hunt syndrome with facial palsy. J Am Optom Assoc 1980;51:296-7. PMID 7372990
- 249
- Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011;86(2):88-93. PMID 21220354
- 250
- Yeo SW, Lee DH, Jun BC, Chang KH, Park YS. Analysis of prognostic factors in Bell's palsy and Ramsay Hunt syndrome. Auris Nasus Larynx 2007;34:159-64. PMID 17055202
- 251
- Yi HA, Lee H. Simultaneous occurrence of trigeminal herpes zoster and Ramsay Hunt syndrome presenting sudden prolonged vertigo. Neurol Sci 2017;38(11):2049-51. PMID 28681308
- 252
- Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005;5:68. PMID 15960856
- 253
- Zajtchuk JT, Matz GJ, Lindsay JR. Temporal bone pathology in herpes oticus. Ann Otol 1972;81:331-8. PMID 5030759
- 254
- Zammit-Maempel I, Campbell RS. Prolonged contrast enhancement of the inner ear on MRI in Ramsay Hunt syndrome. Br J Radiol 1995;68:334-5. PMID 7735780
- 255
- Zhu S, Pyatkevich Y. Ramsay Hunt syndrome type II. Neurology 2014;82(18):1664. PMID 24799517
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- female=male
- Heredity
-
- none
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Zoster [herpes zoster]: B02
- Geniculate herpes zoster: B02.2
- Otitis externa due to herpes zoster: H62.1 + B00.1
- Disorders of the acoustic nerve: H93.3
- Otalgia: H92.0
- Sensorineural hearing loss, unspecified: H90.5
- ICD-11
-
- Acute herpetic geniculate ganglionitis: 1E91.41
- Zoster with other specified complications: 1E91.Y
- Otalgia: AB70.2
- Disorders of acoustic nerve: AB72
- Congenital sensorineural hearing loss: AB50.1
- Acquired sensorineural hearing loss: AB51.1
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Infectious Disorders
Genital herpes: neurologic complications
Nov. 15, 2024
-
Infectious Disorders
Zika virus: neurologic complications
Oct. 08, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Giant cell arteritis
Sep. 25, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Ischemic optic neuropathy
Sep. 25, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Transient visual loss
Sep. 25, 2024
-
Neuro-Oncology
Vestibular schwannoma
Sep. 19, 2024
-
Infectious Disorders
Gram-negative bacillary meningitis
Sep. 13, 2024